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3 Summary 
 
Technology: Infliximab and comparator biological such as adalimumab, etanercept, 
golimumab. 
 
Conditions: Ankylosing spondylitis (AS) 
 
Issue: Infliximab is registered to be used in patients with AS. The aim of the Report is to 
evaluate the clinical efficacy and safety of infliximab and comparator biologicals for the 
treatment of adult AS. 
 
Methods: Systematic literature review and analysis as well as meta-analysis (direct and 
indirect comparison) of published randomised controlled clinical trials (RCT) were 
performed, all relevant health economics literature were identified ad analysed.  
 
Results: Clinical efficacy of biological therapies is based on good clinical evidences 
regarding to all clinical efficacy endpoints (ASAS20, ASAS40, ASAS 5/6, and BASDAI 50% 
response). Altogether, 22 trials are included in our meta-analysis, 12 infliximab, 3 
adalimumab studies, 6 etanercept and 1 golimumab. Efficacy of biological treatments for the 
treatment of AS has been established by clinical scientific evidences, significant improvement 
at all outcomes considered was confirmed. According to the results of indirect comparison, 
there were no significant difference between biological treatments and placebo in terms of 
safety and tolerability endpoints. We found no significant difference between the clinical 
efficacy and safety of infliximab, adalimumab, etanercept and golimumab therapies. Cost-
utility analysis of adalimumab and/or infliximab, etanercept and golimumab treatment for AS 
were performed in the UK, Canada, The Netherlands, Germany, Spain and France. There are 
no cost-utility studies from Eastern Central Europe. 
 
Implications for decision making: Efficacy of infliximab and comparator biologicals for the 
treatment of Ankylosing Spondylitis (AS) was proved by clinical evidence, significant 
improvement at all outcomes considered was confirmed. We found no significant differences 
in efficacy and safety of different biological treatments. Health economics results suggest that 
biological therapies are cost-effective alternatives for the treatment of AS in group of 
developed high income countries. There is a lack of health economics results in Central-
Eastern European countries however these data are more and more required by governments 
and funders as part of the company economic dossiers. 
 
 
  
 
1 Background 
4 Background 
 
4.1 Description of the health problem 
 
Spondyloarthritis (SpA) represents a group of interrelated diseases (ankylosing spondylitis - 
AS, psoriatic arthritis - PsA, arthritis/spondylitis with inflammatory bowel disease, reactive 
arthritis) with common clinical features and a close association with a specific genetic 
predisposition presented by the human leukocyte antigen-27 (HLA-B27). Patients with SpA 
can be distinguished according to their clinical presentation as patients with predominantly 
axial SpA or with predominantly peripheral SpA.  
 
Ankylosing spondylitis (AS), the prototype disease in the spectrum of spondyloarthritides 
(SpA), is a chronic disabling inflammatory disorder, generally starting early in life. 
Inflammatory back pain due to sacroiliitis and spondylitis, and formation of syndesmophytes 
leading to ankylosis of the spine, characterize AS, but the disease may involve also peripheral 
joints, eye, gut and aorta.
56
 The most common extra-articular manifestations in AS are 
represented by uveitis, inflammatory bowel disease, heart, lung, skin, bone and kidney 
involvement.
19
 
 
Back pain is the leading clinical symptom, which presents typically as inflammatory back 
pain that is characterized by morning stiffness and improvement by exercise. In 90% or more 
cases, the disease starts with a sacroiliitis. Further in the course of the disease, the whole spine 
can be affected with spondylitis, spondylodiscitis, and arthritis of the small intervetebral 
joints, however, not all AS patients have or develop syndesmophytes. Even in patients with 
longer-standing disease, syndesmophytes are present in only about 50% of cases and only a 
smaller percentage of these patients develop the typical clinical picture of patients with an 
ankylosed spine, where the name AS comes from. The term AS was introduced around 1900 
at a time when a diagnosis could be made only on the basis of the clinical experience, without 
the help of imaging or laboratory results. It has been suggested that the term axial SpA, 
covering patients early in the course of the disease and patients with a less progressive course, 
seems to be more adequate, whereas the term AS should be reserved for the more advanced 
'ankylosed' phase of the disease.
53
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The mystifying significant male predominance among patients with AS began to abate several 
decades ago along with studies demonstrating a 2–3:1 male-to-female ratio rather than the 
previously thought 5–6:1.56 Very recent studies on patients with axial SpA, which did not 
show any gender difference in disease prevalence, raised the possibility that female patients 
may have some atypical disease manifestations, with inflammatory back pain being less 
frequent on presentation and enthesopathy and generalized pain syndrome heading the clinical 
picture, as well as slower development of typical radiographic changes of AS, as compared to 
males. 
 
Patients with AS suffer from an increased cardiovascular (CV) risk. It appears to be a clear 
contribution of the "traditional" CV risk factors, as well as the underlying chronic 
inflammatory process, to the increased atherosclerotic risk in AS.
45, 48
 
 
Ankylosing spondylitis can have important socioeconomic consequences for individual 
patients and for society. Employment rates for AS patients are significantly decreased in men, 
but not in women when compared to the general population. AS-related sick leave in patients 
in paid work varies between 6.5 and 18 days per patient per year and between 15% and 20% 
of AS patients require help from relatives or friends to complete unpaid tasks.
6
 Cost-of-illness 
studies are available from Brazil, Germany, Hong Kong, Sweden, Spain, Tunisia, The 
Netherlands, Brazil UK and US. The studies that analyse direct and indirect costs report very 
different values but all agree on the fact that the societal impact of AS is mainly related to 
indirect cost (loss of productivity). The most important predictor for high costs both in the 
first and in the fifth year of the disease is functional disability.
47
 In the Czech Republic data 
from two cross sectional studies (Beda I, 2005, n=1008; Beda II, 2008, n=509) were analysed, 
mean age of the samples were 50.2 and 52.5 years, respectively and the disease duration was 
23.0 and 26.4 years. Mean total annual costs per patient in the sample were €4,782 in Beda I 
and €5,806 in Beda II, the average direct costs per patient in the sample per year are estimated 
at €1,812 (Beda I) and €2,588 (Beda II) The largest direct cost burdens were spa procedures 
(45.3 %, Beda I) and biological drugs (52.8 %, Beda II).
49
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4.2 Classification criteria 
 
4.2.1 Modified New York criteria (1984) for diagnosis of ankylosing spondylitis 
(AS) 
 
A definite diagnosis of AS requires the radiological criterion and at least one clinical criterion 
to be satisfied as defined below
64
: 
 
Radiological criterion: 
Sacroiliitis at least grade 2 bilaterally or grade 3 or 4 unilaterally. 
 
Clinical criteria: 
- Low back pain and stiffness for more than 3 months that improves with exercise but is 
not relieved by rest. 
- Limitation of motion of the lumbar spine in both the sagittal and frontal planes. 
- Limitation of chest expansion relative to normal values correlated for age and sex. 
 
All reasonable measures should be taken to ensure that symptoms are due predominantly to 
AS and that alternative causes, including spinal fracture, disc disease and fibromyalgia, are 
excluded. 
 
 
4.2.2 ASAS classification criteria for axial spondyloarthritis (SpA) 
 
The established classification criteria (New York criteria and lately the modified New York 
criteria) for AS date back over 20 years and rely on the combination of clinical symptoms 
plus unequivocal radiographic sacroiliitis of at least grade 2 bilaterally or grade 3 unilaterally. 
However, the radiographs are often normal when symptoms arise and it usually takes several 
years for definite radiographic sacroiliitis to evolve. The most recent Assessment in 
SpondyloArthritis international Society (ASAS) classification criteria for axial 
spondyloarthritis (SpA) were developed for early and established cases and include the 
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magnetic resonance imaging (MRI) technique (active inflammation) and HLA-B27 as an 
important tool for early diagnosis. 
 
ASAS classification criteria for axial SpA covering patients with non-radiographic and 
radiographic axial SpA
52
: 
 
I. In patients with ≥3 months back pain (with/without peripheral manifestation) and 
age onset <45 years: sacroiliitis on imaging plus ≥1 SpA feature OR HLA-B27 
plus ≥2 other SpA features (SpA features are: inflammatory back pain (IBP), 
arthritis, enthesitis (heel), uveitis, dactylitis, psoriasis, Crohn‘s/ ulcerative colitis, 
good response to NSAIDs, family history for SpA, HLA-B27, elevated CRP) 
II. In patients with peripheral manifestations only: arthritis or enthesitis or dactylitis 
plus a.) ≥1 SpA feature (uveitis, psoriasis, Crohn‘s/ulcerative colitis, preceding 
infection, HLA-B27, sacroiliitis on imaging) OR b.) ≥2 other SpA features 
(arthritis, enthesitis, dactylitis, IBP ever, family history for SpA) 
 
 
4.3 Epidemiology of AS 
 
The incidence and prevalence of AS has been studied in various populations. The incidence 
was shown to be relatively stable in northern Norway over 34 years at 7.26 per 100,000. 
Prevalence varied from 0.036% to 0.10%. In Greece and Japan, the incidence and prevalence 
of AS were significantly lower. The incidence mirrors the prevalence of HLA-B27 
seropositivity.
21
 
 
 
4.4 Health status assessment in AS 
 
The Assessment in SpondyloArthritis international Society (ASAS) provides a comprehensive 
handbook on the most relevant aspects for the assessments of spondyloarthritis (SpA), 
including AS.
54
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4.4.1 Disease activity: Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) 
 
The purpose of this tool is to measure patient-reported disease activity in patients with AS. 
The instrument was first published in 1994 using visual analogue scales. The index includes 
patient-reported levels of back pain, fatigue, peripheral joint pain and swelling, localized 
tenderness, and the duration and severity of morning stiffness. Consist of 6 items, the 
response options/scale are numeric response scales (0–10) or visual analogue scales (VAS, 0–
10 cm) anchored by adjectival descriptors “none” and “very severe.” Duration of morning 
stiffness is anchored by a time scale (0–2 or more hours). The BASDAI has been endorsed by 
the Assessment of SpondyloArthritis international Society (ASAS) for the measurement of 
disease activity. The BASDAI has been the most frequently used measure of disease activity 
in clinical trials and is recommended to assess response to anti-tumour necrosis factor 
therapies in AS patients. It is available online (in multiple translations) at http://www.asas-
group.org. For scoring, the scores for questions 5 and 6 (severity and duration of morning 
stiffness) are averaged, the result is then averaged with the remaining 4 question scores to 
give a final score out of 10. BASDAI ranges from 0 (no disease activity) to 10 (maximal 
disease activity). A cut off of 4 is used to define active disease.
65
 
 
 
4.4.2 Disease activity: Ankylosing Spondylitis Disease Activity Score (ASDAS) 
 
To measure disease activity in ankylosing spondylitis (AS) based on a composite score of 
domains relevant to patients and clinicians, including both self reported items and objective 
measures. 
 
Parameters used for the ASDAS are.  
1) Total back pain (BASDAI question 2) 
2) Patient global of disease activity (How active was your spondylitis on average during the 
last week? Response: Visual Analogue Scale – VAS; 0-10 Numerical Rating Scale - NRS) 
3) Peripheral pain/swelling (BASDAI question 3) 
4) Duration of morning stiffness (BASDAI question 6) 
5) C-reactive protein (CRP) in mg/litre (or erythrocyte sedimentation rate (ESR)). 
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Calculation of ASDAS 
ASDAS(CRP): 0.121xtotal back pain+0.110xpatient global+0.073xperipheral 
pain/swelling+0.058xduration of morning stiffness+0.579xLn(CRP+1). 
ASDAS(ESR): 0.113xpatient global+0.293x√ESR+0.086xperipheral 
pain/swelling+0.069xduration of morning stiffness+0.079xtotal back pain. 
ASDAS(CRP) is preferred, but the ASDAS(ESR) can be used in case CRP data are not 
available. (CRP in mg/litre; all patient assessments on a 10 cm scale.) 
 
The ASDAS and aids for its calculation are available online at http://www.asas-group.org. 
The ASDAS was sensitive to improvement with TNF inhibitors in patients with axial 
spondylarthritis. The ASAS group defined 4 important disease states by consensus: inactive 
disease, moderate, high, and very high disease activity, and relevant cut offs between these 
states were calculated from the NOR-DMARD database at 1.3, 2.1, and 3.5 units, 
respectively. Clinically important improvement was found to be 1.1 units or greater and major 
improvement was defined as a change of 2.0 units or more.  
 
 
4.4.3 Functional status: Bath Ankylosing Spondylitis Functional Index (BASFI) 
 
BASFI was developed in 1994 to define and monitor physical functioning in patients with 
AS. Eight items concerning activities referring to the functional anatomy of the patients 
(bending, reaching, changing position, standing, turning, and climbing steps), and 2 items 
assessing the patients’ ability to cope with everyday life. The questionnaire consists of 10 
items, responses are given on numeric response scales (0–10) or visual analogue scale (0–10 
cm) anchored by adjectival descriptors “easy” and “impossible.” BASFI is endorsed by the 
Assessment of SpondyloArthritis international Society. The BASFI is the most widely used 
functional index for assessment of AS patients, primarily in studies of disease impact and in 
clinical trials. BASFI is available online at http://www.asasgroup.org. Scoring: the mean of 
the individual scores is calculated to give the overall index score. Score range is 0–10, with 0 
reflecting no functional impairments and 10 reflecting maximal impairment.
65
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4.4.4 Bath Ankylosing Spondylitis Metrology Index (BASMI) 
 
BASMI dates back to 1994 and it was developed to quantify the mobility of the axial skeleton 
in AS patients and allow objective assessment of clinically significant changes in spinal 
movement. Clinical measures of cervical rotation, tragus to wall distance, lumbar flexion, 
lumbar side flexion, and intermalleolar distance. The tool consist of 5 items, each item is 
scored from 0–10 based on individually defined cut points. Ranges are given as cervical 
rotation (>85.0° to ≤8.5°), tragus to wall (>10 cm to ≤38 cm), lumbar flexion (>7.0 cm to ≤0.7 
cm), lumbar side flexion (>20.0 cm to ≤1.2 cm), and intermalleolar distance (>120 cm to ≤30 
cm). BASMI is endorsed by the Assessment of SpondyloArthritis international Society 
(ASAS).  
 
The BASMI is included in the ASAS core sets as the preferred measure of spinal mobility. It 
has been used in clinical trials of anti–tumour necrosis factor agents in AS patients, and more 
recently was the outcome measure used to show that spinal mobility is determined by both 
spinal inflammation and by structural damage. The BASMI10 is available at  
http://www.asif.rheumanet.org/basmi-10-e.pdf, and the linear version is available at 
http://www.asif.rheumanet.org/basmi-lin-e.pdf. Measurements are performed by health care 
providers who have been trained to perform the clinical examinations required. In the original 
instrument, each continuous assessment was converted into a nominal score of 0, 1, or 2. The 
next year a second nominal version was published, with individual assessments scored 
between 0 and 10. More recently a linear version has been proposed (BASMI-lin), with 
scoring ranges similar to the second nominal version. Individual scores are summed for the 
BASMI-original or averaged for the second nominal BASMI to give a final score between 0 
and 10, where a higher score reflects more significant impairment of spinal mobility. 
Normative values have been published. 
  
  
 
8 Background 
4.4.5 Assessment of treatment response 
 
4.4.5.1 ASAS 20 / 40 improvement criteria 
 
ASAS 20 improvement: 
- Four domains: 
– Patient global (How active was your spondylitis on average during the last week? 
Visual Analogue Scale – VAS; 0-10 Numerical Rating Scale - NRS) 
– Pain (Two questions on average last week, VAS or NRS: – How much pain of your 
spine due to AS do you have? How much pain of your spine due to AS do you have at 
night?) 
– Function (BASFI) 
– Inflammation (mean of BASDAI questions 5 and 6). 
- Improvement of >20% and >1 unit in at least 3 domains on a scale of 10. 
- No worsening of >20% and >1 unit in remaining domain on a scale of 10. 
 
ASAS 40 improvement: 
- Four domains: 
– Patient global (How active was your spondylitis on average during the last week? 
(Visual Analogue Scale – VAS; 0-10 Numerical Rating Scale - NRS) 
– Pain (Two questions on average last week, VAS or NRS: – How much pain of your 
spine due to AS do you have?  How much pain of your spine due to AS do you have at 
night?) 
– Function (BASFI) 
– Inflammation (mean of BASDAI questions 5 and 6). 
- Improvement of >40% and >2 unit in at least 3 domains on a scale of 10. 
- No worsening at all in remaining domain. 
 
ASAS 5/6 criteria 
- Six domains: 
– Patient global (How active was your spondylitis on average during the last week? 
(Visual Analogue Scale – VAS; 0-10 Numerical Rating Scale - NRS) 
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– Pain (Two questions on average last week, VAS or NRS: – How much pain of your 
spine due to AS do you have?  How much pain of your spine due to AS do you have at 
night?) 
– Function (BASFI) 
– Inflammation (mean of BASDAI questions 5 and 6) 
– CRP 
– Spinal mobility (see: ASAS core set) 
- Improvement of >20% in at least five domains. 
 
ASAS partial remission criteria 
- Four domains: 
– Patient global (see Box 26) 
– Pain (see Box 25) 
– Function (see Box 29) 
– Inflammation (mean of BASDAI questions 5 and 6). 
- A value not above 2 units in each of the domains on a scale of 10. 
 
 
4.4.5.2 ASDAS improvement 
 
See section 4.4.2. 
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4.4.6 ASAS core set for disease-controlling antirheumatic treatments 
 
The core set covers the following domains and instruments to be used for the assessment are 
also listed
54
: 
Domain   Instrument 
Function    BASFI 
Pain     Numerical rating scale 0-10 (NRS)/VAS (last week/spine/at 
night due to AS) 
NRS/VAS (last week/spine/due to AS) 
Spinal mobility   Chest expansion 
Modified Schober 
Occiput to wall 
Cervical rotation 
lateral spinal flexion or BASMI 
Patient global    NRS/VAS (global disease activity last week) 
Peripheral joints and 
entheses   Number of swollen joints (44-joint count) 
Validated enthesitis scores, such as MASES, San Francisco and 
Berlin 
x Ray spine    Lateral lumbar spine and lateral cervical spine 
Stiffness    NRS/VAS (duration of morning stiffness/spine/last week) 
Acute phase reactants  C-reactive protein (CRP) or erythrocyte sedimentation rate 
(ESR) 
Fatigue    Fatigue question BASDAI 
 
 
4.5 Management of AS 
 
The ASAS/EULAR recommendations for the treatment of AS were updated in 2010. The 
recommendations were formulated for patients fulfilling the modified New York criteria for 
AS, independent of extra-articular manifestations.
12
 
The recommendations are as follows: 
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The overarching principles of the management of patients with AS are: 
AS is a potentially severe disease with diverse manifestations, usually requiring 
multidisciplinary treatment coordinated by the rheumatologist. 
- The primary goal of treating the patient with AS is to maximise long term health-
related quality of life through control of symptoms and inflammation, prevention of 
progressive structural damage, preservation/normalisation of function and social 
participation. 
- Treatment of AS should aim at the best care and must be based on a shared decision 
between the patient and the rheumatologist. 
- The optimal management of patients with AS requires a combination of non-
pharmacological and pharmacological treatment modalities. 
-  
1. General treatment 
The treatment of patients with AS should be tailored according to: 
- The current manifestations of the disease (axial, peripheral, entheseal, extra-articular 
symptoms and signs). 
- The level of current symptoms, clinical findings, and prognostic indicators. 
- The general clinical status (age, gender, comorbidity, concomitant medications, 
psychosocial factors). 
 
2. Disease monitoring 
The disease monitoring of patients with AS should include: 
- Patient history (eg, questionnaires) 
- Clinical parameters 
- Laboratory tests 
- Imaging 
- All according to the clinical presentation as well as the ASAS core set 
The frequency of monitoring should be decided on an individual basis depending on: 
- Course of symptoms 
- Severity 
-  Treatment 
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3. Non-pharmacological treatment 
- The cornerstone of non-pharmacological treatment of patients with AS is patient 
education and regular exercise. 
- Home exercises are effective. Physical therapy with supervised exercises, land or 
water based, individually or in a group, should be preferred as these are more effective 
than home exercises. 
- Patient associations and self-help groups may be useful. 
 
4. Extra-articular manifestations and comorbidities 
- The frequently observed extra-articular manifestations, for example, psoriasis, uveitis 
and IBD, should be managed in collaboration with the respective specialists. 
- Rheumatologists should be aware of the increased risk of cardiovascular disease and 
osteoporosis. 
 
5. Non-steroidal anti-inflammatory drugs 
- NSAID, including Coxibs, are recommended as first-line drug treatment for AS 
patients with pain and stiffness. 
- Continuous treatment with NSAID is preferred for patients with persistently active, 
symptomatic disease. 
- Cardiovascular, gastrointestinal and renal risks should be taken into account when 
prescribing NSAID. 
 
6. Analgesics 
- Analgesics, such as paracetamol and opioid (like) drugs, might be considered for 
residual pain after previously recommended treatments have failed, are 
contraindicated, and/or poorly tolerated. 
 
7. Glucocorticoids 
- Corticosteroid injections directed to the local site of musculoskeletal inflammation 
may be considered. 
- The use of systemic glucocorticoids for axial disease is not supported by evidence. 
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8. Disease-modifying antirheumatic drugs 
- There is no evidence for the efficacy of DMARD, including sulfasalazine and 
methotrexate, for the treatment of axial disease. 
- Sulfasalazine may be considered in patients with peripheral arthritis. 
 
9. Anti-TNF therapy 
- Anti-TNF therapy should be given to patients with persistently high disease activity 
despite conventional treatments according to the ASAS recommendations. 
- There is no evidence to support the obligatory use of DMARD before or concomitant 
with anti-TNF therapy in patients with axial disease. 
- There is no evidence to support a difference in efficacy of the various TNF inhibitors 
on the axial and articular/entheseal disease manifestations; but in the presence of IBD 
a difference in gastrointestinal efficacy needs to be taken into account. 
- Switching to a second TNF blocker might be beneficial especially in patients with loss 
of response. 
- There is no evidence to support the use of biological agents other than TNF inhibitors 
in AS. 
 
10. Surgery 
- Total hip arthroplasty should be considered in patients with refractory pain or 
disability and radiographic evidence of structural damage, independent of age. 
- Spinal corrective osteotomy may be considered in patients with severe disabling 
deformity. 
- In patients with AS and an acute vertebral fracture a spinal surgeon should be 
consulted. 
 
11. Changes in the disease course 
- If a significant change in the course of the disease occurs, other causes than 
inflammation, such as a spinal fracture, should be considered and appropriate 
evaluation, including imaging, should be performed. 
 
 
A recent update on the role of non-biological therapies in AS confirmed that physical therapy 
in various modalities has positive effects on pain and function in AS. Non-steroidal 
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antiinflamatory drugs (NSAIDs) including coxibs improve standard outcomes (BASDAI, 
BASFI) and disease activity in AS. Disease modifying antirheumatic drugs (DMARDs) have 
no effects on BASDAI, BASFI and pain in AS.
59
 An update on the treatment of AS with 
biologicals stated that all recent literature data support the use of the currently available TNF 
blockers in AS. Data from first studies of patients with nonradiographic SpA show a similar 
response to TNF blockers. There was no change in the incidence of adverse events during 
anti-TNF treatment in SpA.
2
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5 Clinical efficacy and safety of biological medications of ankylosing 
spondylitis 
 
Summary 
Direct and indirect meta-analyses of data from randomized controlled trials identified by 
systematic literature search were conducted to demonstrate the efficacy and safety of 
infliximab, adalimumab, etanercept, golimumab in ankylosing spondylitis. Biological 
therapies were superior to placebo treatment in terms of all efficacy endpoints examined in 
this study (ASAS20, ASAS40, ASAS 5/6, and BASDAI 50% response). No significant 
differences were found between safety and tolerability of biological treatments (infliximab, 
adalimumab, etanercept, golimumab) and placebo in terms of adverse event, serious adverse 
events, adverse events leading to the discontinuation of the therapy, infection, and serious 
infection. According the results of indirect comparison, we found no significant differences 
between the efficacy and safety of different biologic treatments either.  
 
 
5.1 Objectives 
 
The main aims of this systematic review were:  
1. to identify all clinical efficacy and safety evidence for infliximab and comparator 
biological drugs for the treatment of ankylosing spondylitis (AS) 
2. to conduct an up-to-date meta-analysis on efficacy and safety outcomes 
3. to generate an overview of recently published systematic reviews. 
 
Methods used in this analysis were strongly corresponding to NICE Decision Support Unit’s 
recommendations about the evidence synthesis and to Cochrane Handbook’s 
recommendations.
25
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5.2 Methods 
 
5.2.1 Comparators 
 
In this analysis, adalimumab, etanercept and golimumab are considered as comparators for 
infliximab. 
The doses included in the analysis are as follows:  
1. Adalimumab: 40 mg every other week 
2. Etanercept: 25 mg twice weekly, or 50 mg once weekly 
3. Golimumab: 50 mg once a month 
4. Infliximab: 5 mg/kg at 0, 2, 6 weeks and then every 6 to 8 weeks  
 
5.2.2 Search strategies 
 
Electronic databases (Medline and Cochrane Library) as well as references of retrieved 
articles were searched.  
 
In 2007 McLeod et al. published a review, which assesses the comparative clinical 
effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab for the 
treatment of ankylosing spondylitis (AS). Their research strategy covers the RCTs published 
till November, 2005. Until this date we used the list of the RCTs identified by McLeod 2007.   
After this date, the Cochrane Highly Sensitive Search Strategy
25
 was applied to identify 
randomized controlled publications and was combined with the disease name (ankylosing 
spondylitis, ankylosing spondyloarthritis, spondyloarthritide – as well as their combinations) 
and drug names (infliximab, adalimumab, etanercept, golimumab). Meta-analyses were 
identified by applying the relevant publication type limit. Exact search terms are presented in 
Appendix 0. The search dates were 1st November 2005, the end date of the search: 15th 
March 2013.  
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5.2.3 Inclusion and exclusion criteria 
 
5.2.3.1 Inclusion criteria 
 Randomized controlled trials where the full paper can be obtained (studies with only 
abstracts available were excluded) 
 Patients in at least one arm of the trial must receive adalimumab, etanercept, 
golimumab or infliximab treatment. 
 The patients of interest are adults with AS. 
 
5.2.3.2 Exclusion criteria 
 Non randomized or uncontrolled studies, observational studies, case series, letters to 
editor, studies with no abstracts or with conference abstracts only. 
 Trials in diseases other than AS. 
 Off-label doses. 
 Studies reporting solely on laboratory measures aimed at investigating disease, or 
treatment mechanisms and which do not report relevant clinical outcomes. 
 Studies on patients with age <18. 
 Pilot studies. 
 Studies, where study duration is <12 weeks. 
 
5.2.4 Data abstraction 
 
Data were extracted by two independent researchers and checked by a third reviewer. Any 
disagreement was resolved through discussion until consensus was reached.  
Data on the following outcome measures were included: 
Trial characteristics 
o Trial/Reference 
o Population 
o Trial Duration (weeks) 
o Treatment 
o Comparator 
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We evaluate the following efficacy endpoints: 
 
Clinical Efficacy Measures 
 ASAS20 
 ASAS40 
 ASAS5/6 
 ASAS partial remission 
 BASDAI 50% response 
 
ASAS20: 20% improvement response according to the criteria of the ASsessment in 
Ankylosing Spondylitis (ASAS) International Working Group: at least 20% improvement 
from baseline and had an absolute improvement from baseline of at least 1 unit (on a scale of 
0–10) in at least 3 of the following 4 assessment domains: patient’s global assessment, spinal 
pain, function according to the Bath Ankylosing Spondylitis Functional Index (BASFI), and 
morning stiffness (the average of the last 2 questions of the BASDAI). In addition, ASAS20 
responders must not have had deterioration from baseline (defined as a worsening of ≥20% 
and an absolute worsening of at least 1 unit (on a scale of 0–10) in the potential remaining 
assessment domain. 
 
ASAS40 response: 40% improvement from baseline and an absolute improvement of at least 
2 units [on a scale of 0–10] in at least 3 of the 4 assessment domains defined in the ASAS20 
response criteria, with no deterioration from baseline in the potential remaining assessment 
domain), ASAS partial remission (an absolute score of≥2 in each of the above 4 ASAS 
assessment domains) 
 
ASAS5/6: 20% improvement in at least 5 of the following 6 ASAS assessment domains: 
spinal pain, patient’s global assessment, function according to the Bath Ankylosing 
Spondylitis Functional Index (BASFI), morning stiffness, CRP level, and the Bath 
Ankylosing Spondylitis Metrology Index (BASMI) score. 
ASAS partial remission: a value of 2 on a 0–10 scale in each of the 4 domains of the 
ASAS20. 
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BASDAI 50: the proportion of patients who had at least 50% improvement in the BASDAI 
score. 
We distinguish between study endpoints measured at week 12 and 24. 
We also evaluate tolerability and safety of biological therapies.  
 
Tolerability Measures 
 Adverse events leading to discontinuation of therapy  
 
Safety Measures 
 Adverse events 
 Serious adverse events 
 Infections 
 Serious infections 
 Injection-site reaction 
 
5.2.5 Quality assessment 
 
The quality of selected studies was evaluated using the Jadad-score.
32
 This is the most 
frequently used scale in quality assessment of clinical trials.
46
 The Jadad scale assesses the 
quality of published clinical trials based methods relevant to random assignment, double 
blinding, and the withdrawals and dropout of patients. Jadad score ranges from zero to five. 
Detailed description of scoring can be found in Appendices. 
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5.2.6 Comparison 
 
5.2.6.1 Meta-analysis 
 
We have conducted a meta-analysis to compare the efficacy and safety of the biologicals 
included in the study.  
 
Two specific analyses were proceeded for this meta-analysis:  
1. direct comparison: a frequentist meta-analysis of study outcomes for biological 
therapies with adalimumab, etanercept, golimumab and infliximab. 
2. an indirect comparison for therapies with adalimumab, etanercept, golimumab and 
infliximab. 
 
 
5.2.6.2  Direct comparison 
 
Data were analysed using Review Manager 5 software. The Relative Risk (RR) and Rate 
difference (RD) and appropriate 95% CI were derived for each study according to the number 
of events reported in the original studies. Intention-to-treat analysis was conducted. The 
denominators were the total number of patients randomized; missing values were considered 
treatment failures. The pooled RR and RD and 95% CI were calculated using a fixed effect 
model when analyzing efficacy since no significant heterogeneity was detected in the studies, 
and CI were calculated using random effect model when examining safety, since significant 
heterogeneity was identified in relevant number of the cases. The chi-square test for 
heterogeneity was computed with a P-value set to 0.10 to determine statistical significance.  
 
 
5.2.6.3  Mixed treatment comparison 
 
Traditional methods of meta-analysis do not permit indirect comparisons between drugs 
because they only allow us to pool studies with the same comparators. For our second 
analysis, we examined the relative effectiveness of each individual treatment using the Lu’s 
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method for combining direct and indirect evidence in mixed treatment comparisons, a 
Bayesian approach. Statistical models developed by NICE Decision Support Unit (DSU) were 
used. We estimated the posterior densities for all unknown parameters using MCMC (Markov 
chain Monte Carlo) for each model in WinBUGS version 1.4.3. Each outcome measure was 
analysed using random effects models. 
All MTC models used the odds ratio as the measure of relative treatment effect and assumed 
that treatment effects on the odds-ratio scale were multiplicative and exchangeable between 
trials.  
Differences between treatments were considered significantly significant at the 0.05 level if 
the 95% CIs around the odds ratio did not cross. 
The probability of being the best treatment is also reported in the efficacy endpoints for each 
biological. 
Detailed description of methods and WinBUGS codes are provided in Appendix 8.4. 
 
 
5.2.6.4 Presentation of results 
 
We give a detailed description of the included trials identified in the literature and also about 
the quality assessment of each trial. Outcomes of all included RCT trials will be analyzed and 
combined in one meta-analysis. Detailed description of biologics trials appear in Appendices. 
Results of the classical meta-analysis will then be summarized. In Appendices, the detailed 
results from classical meta-analysis will be presented as forest plots diagrams. 
The Bayesian mixed treatment comparison will be presented separately since it includes 
indirect comparisons of biologics. Results will be presented by outcome (e.g., ASAS20, 
ASAS40, ASAS5/6, ASAS partial remission, BASDAI 50% response, adverse events, serious 
adverse events, adverse events leading to the discontinuation of therapy, infections and 
injection-site reactions). 
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5.3 Results: meta-analysis of randomized controlled trials 
 
 
5.3.1 Included studies 
 
5.3.1.1 Results of the search strategy for the period 2005-2013 
 
Our search strategy for the period 1
st
 November 2005 – 15th March 2013 identified 313 items 
(see Appendix 8.2).  
In the first round we excluded non-RCTs, RCTs in other disease (e.g. psoriasis), papers which 
were duplications of RCTs or presented post-hoc analysis of previous RCT results, open-label 
trials and open label extensions of RCT-s. 
Eighteen studies were identified which met the inclusion criteria (see 
Table 1). In the text we refer to the studies by indicating the first author and the year of 
publication. Out of the 18 studies, one study was excluded because it examined low-dose (3 
mg/kg - off-label dose) infliximab therapy
31
, one study examined high dose of etanercept
43
.  
We excluded one study, which examined a narrower study population, patients with HLA 
B27
3
, and two studies, which examined patients with non-radiographic axial 
spondyloarthritis
24, 55
.
i
 Two studies were excluded as infliximab therapy was presented in both 
treatment arms (infliximab+MTX vs infliximab).
37, 40
 Braun 2011
13
 was excluded as this study 
examined the efficacy of etanercept versus sulfasalazine.
ii
 Breban 2008
14
 was excluded as it 
examined infliximab therapy on demand. Hu 2012
26
 was excluded as this study examined 
other end-points than examined in this study. Huang 2010
27
 was excluded because it was a 6 
weeks trial. Cantini 2013
16
 was a long-term follow up study of patients in remission.  
These studies were not included in the meta-analysis however, we present the study design 
and results of infliximab studies in the next chapter. 
                                                 
i
 Axial spondyloarthritis (SpA) may be split into two categories: 1) ankylosing spondylitis (AS) (examined in 
this study) and 2) nonradiographic axial spondyloarthritis (nr-axSpA) by the 1984 modified New York criteria 
which require the presence of sacroiliitis on plain x-ray for the classification of AS 
ii
 Theoretically these three studies could have been included in the mixed treatment comparison, if we had 
identified a study were one treatment arm (comparator) was the same and had been compared to an othe biologs 
(e.g. study 1: etanercept vs sulfasalazine and study 2: sulfasalazine vs biologic other than etanercept. 
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We included five studies identified after November 2005 in the meta-analysis: one 
adalimumab study
28
, three etanercept studies
4, 18, 62
 and one golimumab study
30
. 
 
Table 1 Identified studies 2005-2013 (search after November, 2005) 
References Drug Excl./Incl. 
van der Heijde 2006  etanercept vs. placebo included 
Inman 2008 golimumab vs. placebo included 
Barkham 2010 etanercept vs. placebo included 
Dougados 2011 SPINE etanercept vs. placebo included 
Inman 2010 infliximab vs. placebo excluded: low dose 3mg/kg 
(off label) 
Huang 2013 adalimumab vs. placebo included 
Breban 2008 infliximab vs. infliximab on 
demand 
excluded infliximab on 
demand 
Li 2010 infliximab+MTX vs 
infliximab 
excluded 
Marzo-Ortega 2005 infliximab+MTX vs 
infliximab 
excluded 
Braun 2011 etanercept vs. sulfasalazine excluded 
Barkham 2009 infliximab vs. placebo excluded: other target 
population HLAB27 
Haibel 2008 infliximab vs. placebo excluded: other target 
population (nr-axSpA) 
Sieper 2010 adalimumab vs. placebo excluded: other target 
population (nr-axSpA) 
Navarro-Sarabia 2011 etanercept vs. placebo excluded: high dose (off 
label) 
Huang 2010/11/12 etanercept vs. placebo excluded: 6 weeks 
Cantini 2013 etanercept vs. placebo excluded: long-term follow-
up of patients in remission 
Hu 2012 adalimumab vs. placebo excluded: other end-point 
 
 
5.3.1.2 Inclusion of studies from the period 1995-2005, based on McLeod 2007  
 
Till November, 2005 nine studies identified by McLeod 2007
41
 were screened for our 
enrolment criteria. The search strategy of Huang 2011
29
 identified 9 randomized controlled 
trials on the use of anti TNF- antibodies in AS (see Table 2). 
We excluded one study
10
 as it examined the effect of etanercept at week 6. We have identifies 
in our search that the Wyeth study was published later as a paper by van der Heijde et al. in 
2006, thus, we included this study as van der Heijde 2006 in the analysis.   
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Out of the nine studies identified in McLeod 2007, we included two adalimumab studies
63
 
39
, 
three etanercept studies
15, 17, 23
, two infliximab studies
11, 61
 in the meta-analysis. 
 
Table 2 List of trials identified by McLeod 2007 
References  Excl./Incl. 
Braun 2002 infliximab vs. placebo included 
Gorman 2002 etanercept  vs. placebo included 
Brandt 2003 etanercept vs. placebo excluded: 6 weeks 
Calin 2004 etanercept vs. placebo included 
Davis 2003 etanercept vs. placebo included 
Van der Heijde 2005 
ASSERT 
infliximab vs. placebo included 
Van der Heijde 2006 ATLAS adalimumabvs. placebo included 
Maksymovich 2005  
Canadian AS 
adalimumab vs. placebo included 
Wyeth Study 
 
etanercept 25mg vs. placebo included as van der Heijde 
2006 
 
Altogether, we included 12 trials in our meta-analysis (see Figure 1). 
 
Figure 1 Quorum chart for identification of studies in the systematic review 
 
 
  
313 potentially relevant 
citations retrived 
17 articles remaining for 
more detailed evaluation 
296 irrelevant citations were excluded 
(reviews, studies with different 
diseases, nonrandomized trials, open 
label studies, RCTs on other diseases, 
duplications of RCTs, post-hoc 
analysis of RCTs) 
12 original RCTs were included 
in current review 
12 articles were excluded 
(See Table 1) 
7 studies were taken from McLeod 
2007 
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5.3.2 Description of studies included in the meta-analysis 
 
We included two infliximab studies
11, 61
, three adalimumab studies
39
 
28, 63
, six etanercept 
studies
4, 15, 17, 18, 23, 62
 and one golimumab study
30
 in the meta-analysis. 
One infliximab study
61
, one adalimumab study
63
, one etanercept study
17
 and one golimumab 
study
30
 examined the effect of the therapy at week 24, while the rest examined the efficacy 
and safety of biological therapies during 12 weeks. However, most of the studies lasted 24 
weeks reported endpoints also at week 12. In Heijde 2006 ATLAS and Inman 2008 patients 
could change to early escape in case the therapy was not efficient. The studies had different 
design, three studies examined monotherapy of biologics versus placebo
4, 15, 61
, while the rest 
examined biologics in combination with conventional treatments. 
In the following we shortly present the studies with infliximab included in the meta-analysis. 
The detailed descriptions of the studies included in the meta-analysis are presented in 
Appendix 8.5. 
We also present the study design and results of infliximab studies not included in the meta-
analysis. 
 
 
5.3.2.1 Infliximab studies included in the meta-analysis 
 
Two RCTs with infliximab
11, 61
 encompassing at total of 348 patients were included in this 
review. The used comparator was the placebo in both RCTs. Primary endpoints were the 
BASDAI50 at week 12 and the ASAS20 response at week 24. The secondary endpoints were 
the following: ASAS40, ASAS partial remission, improvements in visual analogue score for 
spinal pain, BASFI, BASMI, SF36, the working group response criteria, concentration of C-
reactive protein in serum, and erythrocyte sedimentation rate, disease activity, physical 
function, range-of-motion assessments, other musculoskeletal assessments, and quality of life. 
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5.3.2.1.1 Braun 200211 
 
Study characteristics: This trial was a multicentre, randomized, placebo controlled study, 
conducted in 11 centres in Germany. The analysis evaluated the effectiveness of infliximab, 
an antibody to tumour necrosis factor, in treatment of patients with active ankylosing 
spondylitis.  
Treatment: Seventy patients were randomized to receive a blinded infusion of infliximab 5 
mg/kg body weight or placebo at week 0, 2 and 6.  
Patients’ characteristics: Patients were excluded if they had active tuberculosis within the 
previous 3 years, specific changes in the radiograph of the chest at baseline, serious infections 
within the previous 2 months. 
Endpoints: The primary endpoint was the improvement of disease activity by 50% between 
baseline and week 12, measured by BASDAI. The trial had some secondary endpoints: 
improvements in visual analogue score for spinal pain, BASFI, BASMI, SF-36, the working 
group response criteria, concentration of C-reactive protein in serum, and erythrocyte 
sedimentation rate. 
Efficacy: Infliximab was effective in every criterion. Eighteen of 34 patients on infliximab 
had a regression of disease activity at week 12 of at least 50% compared with 3 of 35 on 
placebo. As a conclusion the authors stated that treatment with infliximab is effective in 
patients with active ankylosing spondylitis. 
Safety: Three patients had to stop treatment because of adverse events. 
 
 
5.3.2.1.2 Van der Heijde 2005 ASSERT61 
 
Study characteristics: The Van der Heijde trial was a multicentre, randomized, double-blind, 
placebo-controlled study, conducted in 33 centres throughout the US, Canada, and Europe. 
The analysis evaluated the efficacy and safety of infliximab in patients with AS.  
Treatment: In the study, 279 patients with ankylosing spondylitis were randomly assigned to 
receive infusions of placebo or 5 mg/kg infliximab at weeks 0, 2, 6, 12, and 18.  
Patients’ characteristics: Patients were excluded from the study if they had total ankylosis of 
the spine, any other inflammatory rheumatic disease, fibromyalgia, a serious infection within 
2 months prior to randomization, tuberculosis or recent contact with a person with active 
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tuberculosis, infection within 6 months of screening. Previous treatment with anti-TNF 
therapy was prohibited.  
Endpoints: The primary efficacy endpoint was the proportion of patients with a 20% 
improvement response according to the ASAS International Working Group criteria at week 
24. Secondary end points included ASAS40 response, ASAS partial remission, disease 
activity, physical function, range-of-motion assessments, other musculoskeletal assessments, 
and quality of life.  
Efficacy: Patients who received infliximab were more likely to have clinical response (61.2%) 
at week 24 than patients who received placebo (19.2%). Patients receiving infliximab also 
showed significant improvements in the BASDAI, BASFI, BASMI, chest expansion, and 
physical component summary score of the SF-36. 
Safety: Adverse events in both treatment groups were mild or moderate. Adverse events were 
reported by 82.2% of patients receiving infliximab and by 72.0% of patients receiving 
placebo. 
 
 
5.3.2.2 Infliximab studies not included in the meta-analysis 
 
1) Infliximab on demand  
Breban 2008
14
 
Breban study was a randomized, controlled trial that assessed the efficacy of continuous 
treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Of 
247 patients, 124 were assigned to receive infliximab every 6 weeks and 123 to receive on 
demand treatment. The primary end point was the proportion of patients who met the 
ASsessment in AS International Working Group criteria for 20% improvement at week 58. As 
a conclusion the authors stated that continuous treatment of AS with infliximab is more 
efficacious than on-demand treatment. 
 
 
2) Infliximab+MTX 
Li 2008
37
 
Li trial was a randomized, controlled study. The study examined the short-term efficacy and 
safety of MTX in combination with infliximab compared with infliximab and placebo in the 
treatment of AS. Thirty-eight patients with active AS were randomized to receive MTX or 
  
 
28 Clinical efficacy and safety of biological medications of ankylosing spondylitis 
placebo for 22 weeks. The primary efficacy end-point was the percentage of ASAS20 
responders after 30 weeks of treatment. Secondary end-points consisted of symptom 
improvement in individual ASAS domains and improvements in BASFI, BASDAI, CRP and 
Schober test at week 30, ASAS40 responders and lastly, the efficacy including partial 
remission of MTX at week 16. There were no significant differences between the two groups 
at any time points and the secondary outcome showed no significant differences between the 
two groups. 
 
 
 
Marzo-Ortega 2005
40
 
Marzo-Ortega trial was a single-centre, randomized, double-blind, placebo-controlled study 
that evaluated the efficacy and safety of infliximab combined with methotrexate compared 
with methotrexate alone in the treatment of ankylosing spondylitis. Forty-two patients were 
randomized to receive five infusions of either 5 mg/kg infliximab or placebo over 30 weeks. 
The primary endpoint was improvement in disease activity as shown by the BASDAI at week 
30. As a result, the authors stated that infliximab in combination with methotrexate was a safe 
and efficacious treatment, but the additionally received of methotrexate did not sustain 
response for 8 weeks. 
 
3) Other study population 
 
3A) Barkham 2008- HLA B27
3
 
Barkham trial was conducted at the Leeds Teaching Hospitals Trust, Leeds, UK. This was a 
randomized, double-blind, placebo controlled study. The aim of the study was to assess the 
efficacy of infliximab in HLA–B27–positive patients with magnetic resonance imaging 
determined early sacroiliitis. Forty patients were randomised to receive infliximab 5 mg/kg or 
placebo at 0, 2, 6, and 12 weeks. The primary study end point was the change in the total MRI 
score from week 0 to week 16. Infliximab was an effective therapy for early sacroiliitis, 
providing a reduction in disease activity by week 16. 
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3B) SPA  
Bosch 2002
60
 
Bosch trial was a randomized, double-blind, placebo-controlled study that evaluated the 
efficacy profile of infliximab in short term treatment of patients with active 
spondylarthropathy (SpA). Forty patients with SpA were randomly assigned to receive an 
intravenous loading dose (weeks 0, 2, and 6) of 5 mg/kg infliximab or placebo. The primary 
end points of this study were the improvements in patient and physician global assessments of 
disease activity on a 100-mm visual analogue scale. Both primary end points improved 
significantly in the infliximab group, with no improvement in the placebo group. 
 
 
5.3.3 Description of comparator studies 
 
5.3.3.1 Adalimumab studies included in the meta-analysis 
 
Three RCTs
28, 63
 
39
 with adalimumab encompassing at total of 741 patients were included in 
this review. The used comparator was the placebo in every RCT. The primary endpoint was 
the ASAS20 response at week 12. The secondary endpoints were the following: ASAS20 at 
week 24, SPARCC scores, ASAS40, ASAS5/6, high-sensitivity C-reactive protein (hs-CRP); 
percentage of patients achieving ASAS partial remission, BASDAI50, disease activity, pain 
and spinal mobility. 
 
 
5.3.3.2 Etanercept studies included in the meta-analysis 
 
The search yielded 6 RCTs
4, 15, 17, 18, 23, 62
 with etanercept. Six RCTs with etanercept 
encompassing at total of 879 patients were included in this review. The used comparator was 
the placebo in every RCT. Primary endpoints were the ASAS20 at weeks 12 and 24, , 
BASDAI between randomisation and week 12, and in one study the change in AS-WIS
iii
 at 
week 12
4
. The secondary endpoints were the ASAS5/6, ASAS partial remission, ASAS50 and 
                                                 
iii
 Ankylosing Spondylitis Work Instability Scale: a patient-derived outcome measure which allows stratification 
of the risk of job loss
4
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ASAS70, the physician’s global assessment of disease activity, measures of spinal mobility, 
the C-reactive protein level, the BASDAI50, quality of life, functional ability BASFI, HAQ-
DI, improvement in AS-DAS and AS-DAS status. 
 
 
5.3.3.3 Golimumab study included in the meta-analysis 
 
The search yielded one RCT
30
 with golimumab. The RCT encompassing at total of 160 
patients were included in this review. Placebo was used as comparator in the RCT. The 
primary endpoint was the ASAS20 criteria at week 14. The secondary endpoints were the 
ASAS 40% improvement (ASAS40), ASAS partial remission, and 20% improvement in 5 of 
6 ASAS domains (ASAS5/6). 
The number of trials in given comparisons might be different for each endpoint because of the 
distinct endpoint reporting across trials. 
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Table 3 Characteristics of included studies 
Induction 
studies 
N Week Treatment Me
an 
Age 
Disease 
duratio
n 
HLA–
B27 % 
MONO/ 
Combined 
Therapy 
Endpoints 
Infliximab  
Braun 2002 69/70 12 infliximab 5mg/kg at week 
0,2,6 n=34 
2) placebo n=35 
40.6 
 
39.0 
16.4 
 
14.9 
91 
 
88 
MONO Primary: BASDAI50 at week 12 
Secondary: improvements in visual analogue score for spinal 
pain, BASFI, BASMI, SF36, the working group response 
criteria, concentration of C-reactive protein in serum, and 
erythrocyte sedimentation rate 
Van der Heijde 
2005 
ASSERT* 
279 24 infliximab 5mg/kg kg at week 
0,2,6,12,18 n=201 
2) placebo n=78 
40.0 
 
41.0 
7.7 
 
13.2 
 
86.5 
 
88.5 
MONO Primary: number of ASAS20 responders at week 24 
Secondary: ASAS40, ASAS partial remission, disease 
activity, physical function, range-of-motion assessments, 
other musculoskeletal assessments, and quality of life 
Adalimumab   
Huang 2013 344 12 adalimumab 40mg eow  n=229 
2)  placebo n=115 
30.1 
 
29.6 
8.1 
 
7.7 
95.6 
 
94.8 
Combined  Primary: ASAS20 response criteria at week 12 
Secondary: ASAS40, ASAS5/6, high-sensitivity C-reactive 
protein (hs-CRP), BASDAI50, disease activity, pain and 
spinal mobility 
Van der Heijde 
2006 ATLAS 
315 12/24 
rescu
ee 
adalimumab 40mg eow n=208 
2)  placebo n=107 
41.7 
 
43.4 
 
11.3 
 
10.0 
 
78.4 
 
79.4 
 
Combined Primary: ASAS20 at week 12 
Secondary: ASAS20 at week 24 and multiple measures of 
disease activity, spinal mobility, and function, as well as 
ASAS partial remission 
Maksymovich 
2005  
(Lambert 
2007) 
82 12 adalimumab (40mg) n=38 
2) placebo n=44 
41.9 
 
40.0 
14.5 
 
12.1 
NR Combined Primary: ASAS20 response at week 12 
Secondary: SPARCC scores 
Etanercept   
Gorman 2002 40 12 etanercept 25mg twice weekly 
n=20 
2) placebo n=20 
38 
 
39 
15 
 
12 
95 
 
90 
Combined Primary: ASAS20 at week 12 
Secondary: the physician’s global assessment of disease 
activity, measures of spinal mobility, the scores for enthesitis 
and peripheral-joint tenderness, the erythrocyte sedimentation 
rate, and the C-reactive protein level 
Calin 2004 84 12 etanercept 25mg n=45 
2) placebo n=39 
45.3 
40.7 
15.0 
9.7 
NR MONO Primary: ASAS20 at week 12 
Secondary: ASAS 50 and ASAS 70 responses and improved 
scores on individual components of ASAS, the Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI), 
acute phase reactants, and spinal mobility tests 
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Davis 2003 277 24 etanercept 25mg twice weekly 
n=138 
2) placebo n=139 
42.1 
 
41.9 
10.1  
 
10.5 
84 
 
84 
Combined Primary: ASAS20 at weeks 12 and 24 
Secondary: achievement of the ASAS50 and ASAS70 
van der Heijde 
2006  
356 12 etanercept 50 mg once weekly 
n=155 
etanercept 25 mg twice weekly 
n=150 
3) placebo n=51 
41.5 
 
39.8  
 
40.1 
9.0 
 
10.0  
 
8.5 
NR Combined Primary: ASAS20 at week 12 
Secondary: the proportion of responders based on ASAS 40 
and ASAS 5/6 criteria at all time points, BASDAI, serum 
CRP 
Barkham 2010 40 12 etanercept 25mg twice weekly 
n=20 
2) placebo n=20 
40.8  
 
39.4 
11 
 
20 
NR MONO Primary: change in AS-WIS at week 12 
Secondary: assessments of disease activity (BASDAI), 
quality of life, functional ability (Bath Ankylosing 
Spondylitis Functional Index (BASFI), gait parameters using 
an electronic walkway and disability (Disability Index of 
Stanford Health Assessment Questionnaire (HAQ-DI) 
Dougados 
2011 
SPINE 
82 12 etanercept 50mg once weekly  
n=39 
2) placebo n=43 
46 
 
48 
19 
 
23 
79 
 
86 
Combined Primary: BASDAI between randomisation and week 12 
Secondary: ASAS20, ASAS40, ASAS5/6, ASAS partial 
remission, and improvement in BASDAI of at least 50% 
(BASDAI50), improvement in AS-DAS and AS-DAS status 
Golimumab   
Inman 2008 356 14/24 
rescu
e 
golimumab 50mg  every 4 
weeks n=138 
golimumab 100 mg every 4 
weeks n=140 
3) placebo n=78 
38.0 
 
38.0 
 
41.0 
11.0 
 
9.5 
 
16.0 
81.8 
 
84.3 
 
84.6 
Combined Primary: ASAS20 criteria at week 14 
Secondary: ASAS 40% improvement (ASAS40), ASAS 
partial remission, and 20% improvement in 5 of 6 ASAS 
domains (ASAS5/6) 
*median, NR=not reported 
Note: In some cases where the results were only presented as graphs, we read the results from the graphs (Braun 2002, Heijde 2006 ATLAS, 
Inman 2008). 
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5.3.4 Classical meta-analysis: efficacy and safety  
 
 
5.3.4.1 Efficacy 
 
In the meta-analysis we examine the efficacy of infliximab, adalimumab, etanercept and 
golimumab compared to placebo. We present the efficacy results at week 12 and at week 24 
separately.  
 
Efficacy results at week12  
Two infliximab studies
11, 61
, three adalimumab studies
39
 
28, 63
, six etanercept studies
4, 15, 17, 18, 
23, 62
 and one golimumab study
30
 reported efficacy results at week 12 on at least one of the 
efficacy endpoints examined in this study. No infliximab study has reported results on 
ASAS5/6 at week 12. 
All the biological therapies examined in the study (infliximab, adalimumab, etanercept and 
golimumab) proved to be significantly superior to placebo treatment in terms of the efficacy 
end-points at week 12 (ASAS20, ASAS40, ASAS5/6, ASAS partial remission, BASDAI50% 
response). Results of the meta-analysis are presented in Table 4. 
  
  
 
34 Clinical efficacy and safety of biological medications of ankylosing spondylitis 
Table 4 Results of the direct comparison– efficacy at week 12 
Treatment 
Included 
studies 
Included 
patients 
RD  
(fixed effect) 
RR  
(fixed effect) 
ASAS 20 at week 12 
Infliximab vs. placebo 2 348 0.42 [0.32, 0.52] 2.92 [2.02, 4.21] 
Adalimumab vs. placebo 3 741 0.35 [0.28, 0.42] 2.36 [1.90, 2.93] 
Etanercept vs. placebo  5 839 0.34 [0.27, 0.41] 2.11 [1.75, 2.56] 
Golimumab vs. placebo 1 216 0.38 [0.25, 0.50] 2.73 [1.75, 4.24] 
ASAS 40 at week 12 
Infliximab vs. placebo 1 279 0.36 [0.26, 0.46] 3.80 [2.10, 6.90] 
Adalimumab vs. placebo 2 659 0.31 [0.25, 0.37] 3.76 [2.56, 5.53] 
Etanercept vs. placebo  3 478 0.28 [0.19, 0.38] 2.46 [1.63, 3.72] 
Golimumab vs. placebo 1 216 0.30 [0.18, 0.41] 2.92 [1.68, 5.07] 
ASAS 5/6 at week 12 
Infliximab vs. placebo - - - - 
Adalimumab vs. placebo 2 659 0.40 [0.33, 0.46] 4.15 [2.90, 5.94] 
Etanercept vs. placebo  2 438 0.35 [0.25, 0.45] 2.73 [1.77, 4.20] 
Golimumab vs. placebo 1 216 0.42 [0.31, 0.52] 6.41 [2.92, 14.07] 
ASAS Partial remission at week 12 
Infliximab vs. placebo 1 69 0.18 [0.03, 0.32] 7.21 [0.94, 55.50] 
Adalimumab vs. placebo 2 659 0.18 [0.13, 0.22] 5.91 [2.92, 11.94] 
Etanercept vs. placebo  2 438 0.18 [0.11, 0.25] 4.34 [1.74, 10.82] 
Golimumab vs. placebo 1 216 0.18 [0.09, 0.27] 4.52 [1.66, 12.31] 
BASDAI 50 at week 12 
Infliximab vs. placebo 1 69 0.44 [0.25, 0.64] 6.18 [2.00, 19.07] 
Adalimumab vs. placebo 2 659 0.31 [0.25, 0.38] 2.93 [2.14, 4.02] 
Etanercept vs. placebo  3 478 0.34 [0.24, 0.43] 2.80 [1.84, 4.27] 
Golimumab vs. placebo 1 216 0.29 [0.17, 0.40] 2.87 [1.65, 5.00] 
RR: In the case of values >1 the biological therapy is effective.  
RD: In the case of positive values the biological therapy is effective.  
Significant differences between treatments are indicated by bold letters. 
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Efficacy results at week 24 
One infliximab study
61
,one adalimumab study
63
, one etanercept study
17
 and one golimumab 
study
30
 reported efficacy results at week 24 on at least one of the efficacy endpoints examined 
in this study. Davis 2003 did not report results on ASAS40 and ASAS 5/6 and BASDAI50% 
response efficacy endpoints. 
The studies have different study-design. In Heijde 2006 ATLAS and Inman 2008 patients 
could change to early escape in case the therapy was not efficient. They reported results on 
the intention-to-treat population. Heijde 2005 ASSERT examined biologics in monotherapy, 
while the rest examined combined therapies. 
According to the results of the meta-analysis, all the biological therapies achieved 
significantly better results at week 24 in treating AS, than placebo therapy. Results of the 
meta-analysis are presented in Table 5. 
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Table 5 Results of the direct comparison– efficacy at week 24 
Treatment 
Included 
studies 
Included 
patients 
RD  
(fixed effect) 
RR  
(fixed effect) 
ASAS 20 at week 24 
Infliximab vs. placebo 1 279 0.42 [0.31, 0.53] 3.18 [1.99, 5.08] 
Adalimumab vs. placebo 1 315 0.32 [0.22, 0.42] 2.73 [1.80, 4.14] 
Etanercept vs. placebo  1 277 0.34 [0.23, 0.45] 2.53 [1.80, 3.57] 
Golimumab vs. placebo 1 216 0.33 [0.20, 0.45] 2.42 [1.57, 3.72] 
ASAS 40 at week 24 
Infliximab vs. placebo 1 279 0.35 [0.25, 0.45] 4.01 [2.13, 7.55] 
Adalimumab vs. placebo 1 315 0.34 [0.26, 0.42] 7.03 [3.17, 15.58] 
Etanercept vs. placebo  - - - - 
Golimumab vs. placebo 1 216 0.28 [0.17, 0.40] 2.83 [1.62, 4.92] 
ASAS 5/6 at week 24 
Infliximab vs. placebo 1 279 0.41 [0.31, 0.50] 6.27 [2.87, 13.71] 
Adalimumab vs. placebo 1 315 0.33 [0.23, 0.42] 3.68 [2.16, 6.26] 
Etanercept vs. placebo  - - - - 
Golimumab vs. placebo 1 216 0.28 [0.17, 0.39] 3.17 [1.71, 5.84] 
ASAS Partial remission at week 24 
Infliximab vs. placebo 
1 279 0.21 [0.15, 0.27] 
17.46 [2.45, 
124.51] 
Adalimumab vs. placebo 1 315 0.17 [0.09, 0.24] 3.94 [1.74, 8.94] 
Etanercept vs. placebo  1 277 0.12 [0.05, 0.19] 3.86 [1.62, 9.19] 
Golimumab vs. placebo 1 216 0.21 [0.12, 0.30] 5.09 [1.88, 13.76] 
BASDAI 50 at week 24 
Infliximab vs. placebo 1 279 0.40 [0.30, 0.50] 4.90 [2.51, 9.58] 
Adalimumab vs. placebo 1 315 0.27 [0.18, 0.37] 2.83 [1.75, 4.57] 
Etanercept vs. placebo  - - - - 
Golimumab vs. placebo 1 216 0.34 [0.22, 0.45] 3.39 [1.91, 6.03] 
RR: In the case of values >1 the biological therapy is effective.  
RD: In the case of positive values the biological therapy is effective. 
Significant differences between treatments are indicated by bold letters. 
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5.3.4.2 Safety and tolerability 
 
In the meta-analysis we examine the tolerability and safety of infliximab, adalimumab, 
etanercept and golimumab compared to placebo. In the safety analysis we did not distinguish 
the studies based on the duration (12 or 24 weeks). We used random effect models to 
calculate the confidence intervals as we found significant heterogeneity in most of the cases.  
 
We have not found significant differences in safety and tolerability of biological treatments 
compared to placebo in terms of serious adverse events, adverse events leading to 
discontinuation of the therapy, infection, serious infection.  
Nevertheless according to the results significantly more adverse events occur in adalimumab 
therapy groups compared to the placebo group. Injection-site reaction also significantly more 
frequently occurred with adalimumab and etanercept compared to placebo. The results are 
presents in Table 6. 
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Table 6 Results of the direct comparison– safety and tolerability 
Treatment 
Included 
studies 
Included 
patients 
RD  
(random effect) 
RR  
(random effect) 
Adverse events (AE) 
Infliximab vs. placebo 1 279 0.10 [-0.01, 0.22] 1.14 [0.98, 1.33] 
Adalimumab vs. placebo 2 659 0.14 [0.07, 0.21] 1.32 [1.09, 1.61] 
Etanercept vs. placebo  3 478 0.05 [-0.05, 0.15] 1.10 [0.93, 1.31] 
Golimumab vs. placebo 1 216 0.08 [-0.03, 0.19] 1.11 [0.96, 1.28] 
Serious AE 
Infliximab vs. placebo 1 279 0.01 [-0.04, 0.05] 1.30 [0.28, 6.12] 
Adalimumab vs. placebo 2 659 -0.00 [-0.02, 0.01] 0.89 [0.26, 3.04] 
Etanercept vs. placebo  4 483 0.01 [-0.02, 0.05] 1.56 [0.61, 3.94] 
Golimumab vs. placebo 1 216 -0.03 [-0.09, 0.03] 0.56 [0.17, 1.87] 
AEs leading to discontinuation of therapy 
Infliximab vs. placebo 2 348 0.03 [-0.08, 0.15] 1.57 [0.08, 30.88] 
Adalimumab vs. placebo 2 659 0.01 [-0.00, 0.03] 1.73 [0.42, 7.16] 
Etanercept vs. placebo  6 879 0.02 [-0.00, 0.05] 3.14 [0.60, 16.55] 
Golimumab vs. placebo 1 216 0.02 [-0.02, 0.05] 2.23 [0.25, 19.62] 
Infection 
Infliximab vs. placebo 1 279 0.07 [-0.06, 0.19] 1.18 [0.84, 1.66] 
Adalimumab vs. placebo 2 459 0.05 [-0.05, 0.15] 1.34 [0.94, 1.90] 
Etanercept vs. placebo  2 396 0.01 [-0.11, 0.13] 1.10 [0.74, 1.65] 
Golimumab vs. placebo 1 216 0.10 [-0.04, 0.24] 1.28 [0.90, 1.80] 
Serious infection 
Infliximab vs. placebo 1 279 0.01 [-0.01, 0.03] 1.87 [0.09, 38.55] 
Adalimumab vs. placebo 2 459 -0.00 [-0.01, 0.01] 0.51 [0.05, 4.88] 
Etanercept vs. placebo  - - - - 
Golimumab vs. placebo 1 216 -0.01 [-0.05, 0.02] 0.19 [0.01, 4.54] 
Injection-site reaction 
Infliximab vs. placebo 1 279 0.02 [-0.06, 0.09] 1.17 [0.52, 2.62] 
Adalimumab vs. placebo 1 315 0.07 [0.02, 0.12] 3.60 [1.10, 11.80] 
Etanercept vs. placebo  5 839 0.14 [0.08, 0.20] 2.62 [1.77, 3.90] 
Golimumab vs. placebo 1 216 0.06 [0.00, 0.12] 3.35 [0.77, 14.57] 
RR: In the case of values <1 the TNF therapy is safer.  
RD: In the case of negative values the TNF therapy is safer. 
Significant differences between treatments are indicated by bold letters. 
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Mixed treatment comparison: efficacy and safety 
 
5.3.4.3 Treatment relations in the included studies 
 
The same studies were included in the mixed treatment comparison as in the direct 
comparison (see Chapter 5.3.1.1 and Chapter 5.3.1.2). The relations between studies are 
presented in Figure 2. 
 
Figure 2 Studies included in the mixed treatment comparison. 
 
 
 
 
 
 
 
 
5.3.4.4 Results of the mixed treatment comparison 
 
We have carried out indirect comparison of efficacy and safety of infliximab, adalimumab, 
etanercept and golimumab treatments. 
The figures of this section present odds ratios between treatments A and B in the form 
treatmentA-treatmentB (Infliximab always considered as treatment A (the treatment on the 
first place) in the calculations). To read the figures: 
Placebo 
infliximab adalimumab 
etanercept golimumab 
Braun 2002 
Heijde 2005 ASSERT 
Maksymovich 2005 
Heijde 2006 ATLAS 
Huang 2013 
 
Gorman 2002 
Calin 2004 
Davis 2003 
Heijde 2006 
Barkham 2010 
Dougados 2011 
Inman 2008 
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 for ASAS20, ASAS40, ASAS5/6, ASAS partial remission, BASDAI50, if the point 
estimate is less than 1 then the first treatment in the sequence A-B is more effective 
(although not necessarily statistically significantly more effective) 
 for adverse events and tolerability endpoints, if the point estimate is more than 1 then 
the first treatment in the sequence A-B is safer (although not necessarily statistically 
significantly safer) 
Please note that the confidence intervals provide information on whether the difference 
between treatments is statistically significant. If the CI contains 1, the difference is not 
statistically significant. 
 
 
5.3.4.5 Efficacy results at week 12 
 
According to the results of the indirect comparison infliximab therapy was numerically 
superior to adalimumab, etanercept and golimumab therapies in terms of ASAS20, ASAS40 
and BASDAI50 (OR<1), however the differences were not significant. Infliximab studies 
included in the analysis have not reported results for ASAS5/6 at week 12, thus infliximab is 
not included in the indirect comparison of ASAS5/6. In terms of partial remission infliximab 
showed similar results to other biologics. 
No significant differences were found between other biologics either at week 12 in terms of 
ASAS20, ASAS40, ASAS5/6, ASAS partial remission, BASDAI50. 
The results are presented in Figure 3, Figure 4, Figure 5, Figure 6, Figure 7. 
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Figure 3 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS20 at 
week 12 
 
 
 
Figure 4 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS40 at 
week 12 
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Figure 5 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS5/6 at 
week 12 
 
 
 
Figure 6 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS partial 
response at week 12 
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Figure 7 Indirect comparisons, infliximab vs. biologics: Efficacy results – BASDAI50 at 
week 12 
 
 
 
Figure 8 shows the probability of being the best treatment in terms of the five efficacy 
endpoints at week 12 for all the four biologics examined. Infliximab shows a 60% probability 
of being the best treatment of all in terms of ASAS20 improvement at week 12. Adalimumab, 
etanercept and golimumab show probabilities of 6%, 3% and 30%, respectively. 
Figure 8 Indirect comparisons, infliximab vs. biologics: Probability of being the best 
treatment at week 12 
 
Note: No infliximab studies reported results on ASAS5/6 endpoint. 
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5.3.4.6 Efficacy results at week 24 
 
Infliximab therapy was numerically superior to adalimumab, etanercept and golimumab 
therapies in terms of all the efficacy endpoint at week 24 (except for ASAS40 compared to 
adalimumab), however the difference were not statistically significant. No significant 
differences were observed between other biologics either at week 24 in terms of ASAS20, 
ASAS40, ASAS5/6, ASAS partial remission, BASDAI50. 
The results are presented in Figure 9, Figure 10, Figure 11, Figure 12, Figure 13. 
Figure 9 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS20 at 
week 24 
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Figure 10 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS40 at 
week 24 
 
 
 
Figure 11 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS5/6 at 
week 24 
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Figure 12 Indirect comparisons, infliximab vs. biologics: Efficacy results – ASAS partial 
response at week 24 
 
 
 
Figure 13 Indirect comparisons, infliximab vs. biologics: Efficacy results – BASDAI50 at 
week 24 
 
 
 
Figure 14 shows the probability of being the best treatment in terms of the five efficacy 
endpoints at week 24 for all the four biologics examined. Infliximab shows a 66% probability 
of being the best treatment of all in terms of ASAS20 improvement at week 12. Adalimumab, 
etanercept and golimumab show probabilities of 12%, 11% and 10%, respectively. 
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Figure 14 Indirect comparisons, infliximab vs. biologics: Probability of being the best 
treatment at week 24 
 
 
Note: No infliximab studies reported results on ASAS5/6 endpoint. 
 
5.3.4.7 Safety, tolerability 
 
No significant differences were observed between infliximab and other biologics in terms of 
adverse events, serious adverse events, adverse events leading to the discontinuation of 
therapy, infection and injection site reactions (See Figure 15, Figure 16, Figure 17, Figure 18, 
Figure 19). 
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Figure 15 Indirect comparisons, infliximab vs. biologics: Safety results – Adverse events 
 
 
 
Figure 16 Indirect comparisons, infliximab vs. biologics: Safety results – Serious adverse 
events 
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Figure 17 Indirect comparisons, infliximab vs. biologics: Safety results – Adverse events 
leading to discontinuation of therapy 
 
 
 
Figure 18 Indirect comparisons, infliximab vs. biologics: Safety results – Infections 
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Figure 19 Indirect comparisons, infliximab vs. biologics: Safety results – Injection site 
reactions 
 
 
 
 
5.4 Review of previously published meta-analyses 
 
We conducted a simple MEDLINE search on meta-analysis with biologics in AS. In this 
chapter we shortly present the results of these meta-analyses. 
 
McLeod 2007
41
- adalimumab, etanercept and infliximab 
The objective of the study was to assess the comparative clinical effectiveness and cost-
effectiveness of adalimumab, etanercept and infliximab for the treatment of ankylosing 
spondylitis (AS). The authors included nine placebo controlled RCTs in the meta-analysis 
(See Table 2). We used this study to identify RCTs, which meet our enrolment criteria, till 
November 2005. The end-points considered in the study ASAS 20, 50 and 70% improvement 
and mean change in BASDAI and BASFI at 12 weeks following initiation of anti-TNF-alpha 
therapy or placebo for all three drugs. Meta-analyses were also conducted at 24 weeks for 
etanercept and infliximab. According to the results of the meta-analysis “in the short term (12-
24 weeks) the three treatments are clinically effective in relation to assessment of ASAS, 
BASDAI and BASFI over placebo/conventional treatment. Indirect comparisons of treatments 
were limited and did not show a significant difference in effectiveness between the three 
agents.” 
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Boyce 2010 - golimumab
9
 
The goals of this article were to review the literature on the efficacy and safety of golimumab 
in RA, PsA and AS. 
One clinical study was identified and used to evaluate the efficacy and tolerability of 
golimumab in patients with AS, where golimumab (subcutaneous) was more effective than 
placebo in terms of ASAS20 and ASAS40.  
Regarding safety (considering all the three disease) “the incidence of any adverse effect 
appeared to be comparable in the GLM (61.2%-93.9%) and placebo groups (59.3%-85.3%), 
but withdrawals because of adverse effects were higher in the GLM groups (0%-12.1%) than 
in the placebo groups (0%-5.9%). The incidence of serious infections was comparable for 
GLM (0%-4.4%) and placebo (0.8%-3.5%). The most frequently reported adverse effects in 
the GLM groups were injection-site reactions (2.7%-37.1%), nausea (2.7%-22.9%), headache 
(3.8%-21.2%), nasopharyngitis (1.9%-15.0%), and upper respiratory tract infections (5.7%-
13.8%).” 
 
Poddubnyy 2011 - adalimumab
50
 
The objective of the study is to summarize the available data on short- and long-term efficacy 
and safety of adalimumab in the treatment of rheumatoid arthritis, ankylosing spondylitis and 
psoriatic arthritis. The review included four adalimumab studies in AS (three of them were 
open-label studies). The authors find that “adalimumab is effective and reasonably safe in the 
short- and long-term treatment of patients with AS as well as patients with rheumatoid 
arthritis and psoriatic arthritis who do not respond to the standard therapy”.  
 
Li 2012 – etanercept38 
The objective of the study was to conduct meta-analysis to investigate the efficacy and safety 
of etanercept is AS and to compare the different responses between the Caucasian population 
and the Chinese population. The meta-analysis included fourteen randomized, double-blind, 
placebo-controlled clinical trials with 1,570 participants. The endpoints examined in the study 
were: ASAS20, ASAS40, ASAS5/6, and partial remission, BASFI, BASDI, BASMI, patient’s 
global assessment, total back pain, nocturnal pain, chest expansion, morning stiffness, tender 
joint score, swollen join score, and occiput-to-wall as well as laboratory outcomes (CRP, 
ESR). According to the result “there was sufficient evidence to prove that etanercept has its 
advantages in both disease activity controlling and symptoms relieving, especially for axial 
joints compared with peripheric joints, without higher incidence of serious adverse events. 
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The preliminary analysis also provided that “the Caucasian population has better response to 
etanercept treatment, with more treatment-emergent adverse events.”  
 
Migliore 2012 - adalimumab, etanercept and infliximab
42
 
The objective of the study was to compare ASAS 20 response at 24 weeks between anti-TNF 
biological agents in patients with AS by means of a mixed treatment comparison of different 
randomized, controlled trials (RCTs) on the efficacy of biological therapies. 
Altogether three RCTs were included in the mixed treatment analysis. According to the 
results, anti-TNF agents demonstrated to be more efficacious in inducing an ASAS20 
response than placebo. “Infliximab shows a 72% probability of being the best treatment of all. 
Adalimumab and etanercept show probabilities of 13% and 15%, respectively. No differences 
were observed when comparing directly an anti-TNF-α agent against another. When 
compared with placebo, Infliximab increases the probability of response by ∼7-times 
(OR  =  6.8), Adalimumab by ∼4-times (OR  =  4.4), and Etanercept by 5-times 
(OR  =  4.9).” 
 
Thaler 2012 - Drug Class Review: Targeted Immune Modulators
57
 
Thaler 2012 systematically compared the efficacy, effectiveness, and safety (adverse events) 
of abatacept, adalimumab, alefacept, anakinra, certolizumab pegol, etanercept, golimumab, 
infliximab, natalizumab, rituximab, tocilizumab, and ustekinumab in patients with rheumatoid 
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s 
disease, ulcerative colitis, and plaque psoriasis based on literature published between 2009 
(January) to 2011 (October). 
According to the authors the “targeted immune modulators are highly effective medications 
for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, 
psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis that substantially 
improve the burden of disease and are generally safe for short-term treatment”. 
 
Baraliakos 2012
2
 
Baraliakos et al. performed a literature review as basis for the update of the Assessment in 
SpondyloArthritis international Society/European League Against Rheumatism 
(ASAS/EULAR) treatment recommendations with biologics in AS. 
According to their results 98 papers contained efficacy data and 25 had complete data for 
analysis. “The treatment effect sizes (95% CI) for anti-TNF vs placebo varied between 0.34 
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(0.08, 0.6) and 1.5 (0.45, 2.5) for BASDAI and 0.33 (0.07, 0.59) and 2.5 (1.3, 3.7) for BASFI. 
The calculation of the numbers needed to treat all the different outcomes varied between 2.3 
and 3.0 patients for all ASAS outcomes and between 2.7 and 6.5 patients for ASAS partial 
remission. Data on biologics other than anti-TNF and for TNF blockers on juvenile SpA were 
limited. The incidence rates of uveitis during anti-TNF treatment varied between 4.4/100 
patient-years (pys) and 15.6/100  pys during placebo (P  <  0.05). The incidence rates of 
IBD flares were significantly less during infliximab treatment (0.2/100  pys). The rate of 
infections was higher in patients treated with anti-TNF as compared with placebo, but there 
was no difference in the incidence of serious infections for treatment with anti-TNF vs 
placebo”. 
 
 
5.5 Conclusions 
 
 
5.5.1 Efficacy and safety 
 
Our review delivers both direct and indirect comparisons of the efficacy and safety of four 
biologics for ankylosing spondylitis from double-blind, placebo-controlled trials. Firstly, a 
classical direct meta-analysis was undertaken to obtain summary estimates of clinical 
effectiveness and safety. Following recent NICE guidelines, a mixed treatment comparison 
was undertaken allowing for indirect comparisons in the absence of head-to-head trials. 
The systematic search identified twelve RCTs. Most studies were of good internal validity 
and compared one biologic to placebo (with or without methotrexate or sulfasalazine).  
Generally, biologics showed similar efficacy and safety profile. The meta-analysis showed 
that all biologics demonstrated statistically significant improvements compared to placebo 
with respect to ASAS20, ASAS40, ASAS5/6, ASAS partial remission, BASDAI50 
improvements both at week 12 and 24. Regarding safety, we have not found significant 
differences between biologics and placebo treatments either in terms of adverse event, serious 
adverse events, adverse events leading to the discontinuation of the therapy, infection, and 
serious infection. According the results of the mixed treatment comparison no significant 
differences were observed between the different types of biologic treatments in terms of the 
efficacy and safety endpoints examined in the study. 
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5.5.2 Limitations 
 
A potential weakness of this meta-analysis arises from the fact that the trials from which data 
are combined are likely to differ in their design (e.g. in the analysis we did not distinguish 
between mono and combined therapies). 
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6 Biological therapies for the treatment of AS – systematic review of 
the health economic literature 
 
Summary 
The cost-utility of infliximab, etanercept, adalimumab and golimumab was analysed in the 
UK, The Netherlands, Spain, France, Germany and Canada. Among the biologicals, 
infliximab was the most frequently studied. Depending on model assumptions the incremental 
cost-effectiveness ratio (ICER) varied broadly. Available cost-utility analyses suggest that 
anti-TNF therapies are cost-effective treatments in AS in these European countries. 
Nevertheless, most of the studies included only one biological drug which was compared to 
conventional treatment, thus we cannot draw conclusion regarding the comparative cost-
effectiveness of different biologicals and the optimal anti-TNF treatment sequence. 
For countries from Central and Eastern Europe, cost-utility data are lacking regarding 
biological treatment of AS. Transferability of cost-effectiveness findings from one country to 
another is limited, thus country-specific evaluations are required to take into account country-
specific features. 
 
 
6.1 Literature search 
 
Our aim was to systematically review the literature for health economic evaluations of 
adalimumab, etanercept, golimumab and infliximab for the treatment of AS. 
Gaujoux-Viala et al. performed a systematic literature review for articles published up to 
November 2010, we rely on findings of this extensive report.
22
  
We have performed a complementary search for the time period between November 2010 and 
March 2013 which ran in the following databases: Ovid MEDLINE(R) 1946 to Present with 
Daily Update, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Web of 
Knowledge. The search strategies applied are presented in Appendix 8.7. Additionally, the 
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websites of the National Institute for Health and Care Excellence (NICE) and Canadian 
Agency for Drugs and Technologies in Health (CADTH) were search for relevant reports. 
Original articles of full economic evaluations presenting cost-utility data (cost/QALY) of 
biological therapies (adalimumab, etanercept, golimumab, infliximab) for AS were retrieved 
by two independent reviewers. Articles with full text in English were analysed and a short 
descriptive summary of each is provided. 
 
 
6.2 Results 
 
The review by Gaujoux-Viala et al. discussed ten articles analysing the health economics of 
adalimumab, etanercept, infliximab. One article was excluded from our report as that was not 
a cost-utility analysis.
5
 Altogether nine articles were considered from this review for the 
current HTA report.
1, 7, 8, 20, 33-36, 44
 
 
The number of hits of the complementary literature search and included articles were as 
follows (articles overlapping between databases are listed only where first appeared): 
- Ovid MEDLINE(R) 1946 to Present with Daily Update – 7 hits / 0 articles included 
- Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations – 3 hits / 0 articles 
included 
- Web of Knowledge – 39 hits / 1 article included 
- National Institute for Health and Care Excellence (NICE) - 1 report included 
- Canadian Agency for Drugs and Technologies in Health (CADTH) - 0 report included 
 
The list of hits and reasons of exclusion are presented in Appendix 8.8. 
 
In the next sections we present the nine cost-utility studies (up to November 2010) discussed 
by Gaujoux-Viala et al.
22
 and introduce the two publications from our additional search 
(2010-2013). 
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6.2.1 Systematic review by Gaujoux-Viala et al. (2012) 
 
Nine articles reporting the cost-utility of TNF inhibitors in AS patients have been published: 
five for infliximab
20, 33-36
, one infliximab or etanercept against conventional treatment
7
, two 
for etanercept
1, 44
, and one for adalimumab
8
. 
 
Kobelt et al, UK (2004)
33
 
Kobelt et al examined the use of infliximab in the UK with a 2-year time horizon in the base 
case analysis and a 30-year time horizon in sensitivity analyses from a societal perspective. 
Treatment increased the number of QALYs by 0.175, leading to a cost per QALY gained of 
£35 400 for the first year of treatment. When treatment was assumed to continue for the full 2 
years the cost per QALY was £32,800. When infliximab infusions were given every 8 weeks 
instead of every 6 weeks, the cost per QALY was reduced to £17,300. In the long-term model, 
the cost per QALY was estimated at £9,600. 
 
Kobelt et al, Canada (2005)
34
 
The UK model (Kobelt 2004) was adapted to examine the use of infliximab in Canada. Over a 
30-year time frame the cost per QALY gained in the societal perspective was $Can37,491. 
Assuming that disease in patients on treatment progresses at half the rate of that of untreated 
patients, the cost-effectiveness ratio was $Can45,121, and with the most conservative 
assumption that disease progression is the same in both arms, the ratio was $Can54,137. The 
results were sensitive to the dosing regimen adopted, the discontinuation rate and the 
assumptions concerning disease progression while on treatment. 
 
Boonen et al, The Netherlands (2006)
7
 
This analysis examined the use of infliximab or etanercept in the Netherlands from a societal 
perspective. Markov model over five years with cycle times of three months was computed. 
Utilities and costs assigned to the BASDAI disease states were derived from a two year 
observational Dutch cohort. The incremental cost-utility ratios (ICURs) varied from €67,207 
to €237,010 for infliximab as compared with usual care. The ICUR for etanercept was 
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between €42,914 and €123,761 per QALY for etanercept compared with usual care. The 
model was sensitive to drug prices. 
 
Kobelt et al, UK (2007)
35
 
Kobelt et al. compared the cost effectiveness of treating AS with infliximab in the UK over a 
lifetime using a Markov model, with data estimated from two different clinical trials and 
adjusted for clinical practice guidelines. From the societal perspective and under the 
assumption that disease activity would be controlled and functional capacity would remain 
stable while on the drug, treatment with infliximab dominated standard treatment. From the 
UK National Health Service perspective, the cost per QALY gained over a lifetime was 
£28,300 and £26,800 for the two trials. If functional capacity were to deteriorate at half the 
rate of that for untreated patients the cost per QALY gained would be £35,300 and £34,100, 
respectively. Results were sensitive to the dosing regimen adopted, the discontinuation rate 
and the assumptions concerning disease progression while on treatment. 
 
Ara et al, UK (2007)
1
 
A mathematical model based on BASDAI and BASFI was constructed to estimate the costs 
and benefits associated with etanercept plus NSAIDs as compared with NSAIDs alone in the 
UK. Individual patient data from phase III RCTs trials were used to inform the proportion and 
magnitude of initial response to treatment and changes in health related quality of life. Over a 
25-year time horizon, etanercept plus NSAIDs gave 1.58 more QALYs at an additional cost 
of £35,978 as compared with NSAIDs alone. This finding equates to an estimate of £22,700 
per QALY. The ICER (cost per QALY) with shorter time periods was £27,600, £23,600 and 
£22,600 at 2, 5 and 15 years, respectively. With a 25-year time horizon, 93% of results from 
the probabilistic analyses fell below a threshold of £25,000 per QALY. 
 
Kobelt et al, Spain (2008)
36
 
 The Kobelt model (2007, UK) was adapted to examine the use of infliximab in Spain. Cost-
effectiveness estimates were based on a placebo-controlled clinical trial and an open clinical 
study in Spain. From the societal perspective, infliximab treatment dominated standard 
treatment in both analyses. From the perspective of the healthcare system, with the 
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assumption that over the long term the functional ability of patients on treatment would 
decline at half the natural rate, the cost per QALY gained was estimated at €22,519 (double-
blind trial) and €8866 (open study). Assuming that patients’ function on treatment remains 
stable, the cost-effectiveness ratios were €15,157 and €5,307, respectively. Under the most 
conservative assumption (no effect of treatment on progression), the ratios were €31,721 and 
€13,659, respectively. In addition, the results were sensitive to the time horizon and 
discontinuation rates. 
 
Fautrel et al, France (2010)
20
 
A recent study in France compared two therapeutic regimens: infliximab every 6 weeks and 
on demand, for AS. Data were collected by phone every 3 months for 1 year, direct and 
indirect costs were calculated from a payer perspective. Health-related quality of life was 
assessed by a general health rating scale. The ICERs for every 6 weeks in comparison to the 
on-demand regimen was €50,760 for one QALY gained.  
 
Neilson et al, Germany (2010)
44
 
The model by Ara et al (2007) was adapted to examine the use of etanercept in Germany. In 
the base case, etanercept plus usual care yielded 1,475 more QALYs at an additional cost of 
€80 827,668 (social health insurance perspective) or €32 657,590 (societal perspective), for an 
ICER of €54,815 per QALY and €22,147 per QALY, respectively. Over a shorter time 
horizon of 10 years, the ICERs were €59,006 and €29,815 for social health insurance and 
societal viewpoints, respectively. Assumptions having the largest impact on results included 
withdrawal rates from etanercept, quality of life, disease costs and initial response. 
 
 
Botteman et al, UK (2007)
8
 
This study evaluated the cost-effectiveness of adalimumab versus conventional therapy in 
patients with AS and used pooled data from two phase III studies of adalimumab in active AS. 
The central estimate was that, over 30 years, adalimumab therapy yielded 1.03 more QALYs 
per patient. Some AS treatment-related costs were estimated to be offset by adalimumab (at 
£10,750/patient), for a total incremental cost (adalimumab vs conventional therapy) of 
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£23,857 per patient. The 30-year ICER of adalimumab versus conventional therapy was 
estimated at £23,097 per QALY. When applying societal perspective (indirect costs were 
included), the ICER improved to £5,093 per QALY. 
 
 
6.2.2 Articles revealed by the additional search 
 
Riemsma et al, UK (2011)
51
 
In this report the manufacturer analysis the cost-utility of golimumab in AS using a de novo 
economic model were published. The model compares: 
- golimumab 50 mg given once a month, on the same date each month against three different 
treatments: 
- adalimumab (40 mg adalimumab administered every other week as a single dose), 
- etanercept (25 mg administered twice weekly, or 50 mg administered once weekly), 
- conventional therapy (non-biologic DMARDs, NSAIDs, Cox-2 inhibitors, and 
physiotherapy). 
In the base-case model, a decision is made to continue or withdraw from TNF-α inhibitors 
according to probability of response defined as 50% improvement in BASDAI at 12 weeks. 
After the initial decision tree, patients enter a Markov model with a cycle length of 12 weeks 
and a time horizon in the base case of 20 years (maximum 60.1 years (up to age 100)). If 
patients are on TNF-α inhibitors, they either stay on therapy („On treatment‟), or discontinue 
due to lack of efficacy or adverse events („Not on TNF-α‟). To model the lower disease 
activity just after discontinuation of TNF-α inhibitor therapy two 12-week tunnel states („Just 
discontinued‟ and „Discontinued‟) were incorporated in the model. Patients in the 
conventional treatment arm enter the Markov model in the „Not on TNF-α‟ state. Patients can 
die at any point in the model. SAEs and injection site reactions of TNF-α inhibitors treatments 
are included in the model. In the base case analysis the costs and QALYs of golimumab were 
comparable to those of the other TNF-α inhibitors. The ICER of golimumab versus 
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conventional care is £26,597. Adalimumab and etanercept are extended dominated by 
golimumab. The evidence review group highlights that based on rates for discontinuation and 
adverse events from the mixed treatment comparison and with model corrections made, 
golimumab is less effective than the other two TNF-α inhibitor treatments and would not be 
cost effective at any willingness to pay threshold. This does not preclude there being value in 
the use of golimumab as second-line therapy. The current model structure does however not 
allow the evaluation of sequential use of golimumab. 
 
Tran-Duy et al., The Netherlands (2011)
58
 
Long-term quality of life, societal costs and cost- effectiveness as affected by sequential drug 
treatment strategies for AS was modelled in The Netherlands. Discrete event simulation 
paradigm was selected for model development and societal perspective was used for the 
analysis. Drug efficacy was modelled as changes in BASDAI and BASFI which were linked 
to costs and health utility using statistical models fitted based on an observational AS cohort. 
Clinical efficacy was based on clinical data. Two strategies were compared: (1) five available 
non-steroidal anti-inflammatory drugs (strategy 1) and (2) same as strategy 1 plus two tumour 
necrosis factor α inhibitors in a random order for each patient (strategy 2). The time horizon 
was 70 years with intervals of 1–3 months. Incremental cost per QALY gained in strategy 2 
compared with strategy 1 was €35,186. At a willingness-to-pay threshold of €80,000, it was 
99.9% certain that strategy 2 was cost-effective. 
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6.3 Discussion, conclusions 
 
The cost-utility of infliximab, etanercept, adalimumab and golimumab was analysed in 
various studies from the UK, The Netherlands, Spain, France, Germany and Canada. Most of 
the studies compared anti-TNF treatment with conventional therapy. Among the biologicals, 
infliximab was the most frequently studied: UK 2, The Netherlands 1, Spain 1, France 1, 
Canada 1 study. 
Depending on model assumptions (time horizon, drug price, dosing regimens, discontinuation 
rate, assumptions concerning disease progression while on treatment, perspective of the 
analysis) the incremental cost-effectiveness ratio (ICER) varied broadly. 
In the UK, taking societal perspective, the ICER of infliximab compared to conventional 
treatment was £35,400 per QALY for the first year of treatment, but when treatment was 
assumed to continue for 2 years, the cost per QALY was £32,800. When infliximab infusions 
were given every 8 weeks instead of every 6 weeks, the cost per QALY was reduced to 
£19,400. The ICER was £9,600/QALY on the 30-years horizon.33 In another analysis from the 
UK, infliximab dominated standard treatment on the life-time horizon from the societal 
perspective, and ICER was £28,300 and £26,800 from the NHS perspective. The ICER of 
etanercept vs. conventional treatment in the UK from the NHS perspective was £27,600, 
£23,600 and £22,600 per QALY at 2, 5 and 15 years, respectively.1 The 30-year ICER of 
adalimumab vs. conventional therapy in the UK from the NHS perspective was estimated at 
£23,097 per QALY, and £5,093 per QALY from the societal perspective.8 
In The Netherlands, taking societal perspective the ICER varied from €67,207 to €237,010 for 
infliximab as compared with usual care, and the ICER was between €42,914 and €123,761 per 
QALY for etanercept compared also with usual care.
7
 
In France, two treatment strategies of infliximab were compared: every 6 weeks vs. on 
demand, the ICER of the every 6 weeks strategy was €51,000 per QALY.20 
In Germany, ICER of etanercept vs. usual care on a 25-year horizon was €54,815 per QALY 
(social health insurance perspective) and €22,147 per QALY (societal perspective), 
respectively.
44
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In Spain, taking the societal perspective infliximab treatment dominated standard treatment 
and from the perspective of the healthcare system, the cost per QALY gained was estimated at 
€8,866 - €22,519 on a 40-year horizon.36 
 
Two studies considered more than one biological drug. In the UK, cost-utility of golimumab 
was analysed against two other anti-TNF treatment strategies (adalimumab and etanercept) 
and conventional treatment, however infliximab was not considered as a comparator. In this 
analysis the ICER of golimumab versus conventional care was £26,597 and adalimumab and 
etanercept were extended dominated by golimumab.
51
 In The Netherlands a treatment 
including five available NSAIDs was compared to a treatment with two TNF-alfa inhibitors 
(one subcutaneously and one intravenously administered drug randomly chosen from two 
possible drugs) in a random order for each patient on a 70-years horizon, and the ICER of the 
latter was €35,186.58 
 
To sum up, available cost-utility analyses suggest that anti-TNF therapies are cost-effective 
treatments in AS in the UK, Germany, Spain, Germany and The Netherlands. We find 
important to highlight two aspects. Not all biological were studied in all the five countries. 
Furthermore, most of the studies included only one biological drug which was compared to 
conventional treatment. The only analysis which compared different biological treatment arms 
did not cover the whole available spectrum of anti-TNF therapies.
51
 Therefore, we cannot 
draw conclusion regarding the comparative cost-effectiveness of different biologicals and the 
optimal anti-TNF treatment sequence. 
For countries from Central and Eastern Europe, health economics data are lacking regarding 
biological treatment of AS. Transferability of cost-effectiveness findings from one country to 
another is limited, thus country-specific evaluations are required to take into account country-
specific features such as treatment policies, epidemiology of AS, service patterns and unit 
costs. 
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8 Appendices 
 
8.1 Search terms for RCTs and meta-analyses 
(("spondylitis, ankylosing"[MeSH Terms] OR ("spondylitis"[All Fields] AND "ankylosing"[All Fields]) OR 
"ankylosing spondylitis"[All Fields] OR ("ankylosing"[All Fields] AND "spondylitis"[All Fields])) OR 
("spondylitis, ankylosing"[MeSH Terms] OR ("spondylitis"[All Fields] AND "ankylosing"[All Fields]) OR 
"ankylosing spondylitis"[All Fields] OR ("ankylosing"[All Fields] AND "spondyloarthritis"[All Fields]) OR 
"ankylosing spondyloarthritis"[All Fields]) OR ("spondylitis, ankylosing"[MeSH Terms] OR ("spondylitis"[All 
Fields] AND "ankylosing"[All Fields]) OR "ankylosing spondylitis"[All Fields] OR ("ankylosing"[All Fields] 
AND "spondyloarthritides"[All Fields])) OR ("spondylarthritis"[MeSH Terms] OR "spondylarthritis"[All Fields] 
OR "spondylarthritides"[All Fields])) AND (("adalimumab"[Supplementary Concept] OR "adalimumab"[All 
Fields]) OR ("infliximab"[Supplementary Concept] OR "infliximab"[All Fields]) OR 
("golimumab"[Supplementary Concept] OR "golimumab"[All Fields]) OR ("TNFR-Fc fusion 
protein"[Supplementary Concept] OR "TNFR-Fc fusion protein"[All Fields] OR "etanercept"[All Fields])) AND 
((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR 
"clinical trials as topic"[MeSH Terms] OR randomly[tiab] OR trial[ti]) NOT ("animals"[MeSH Terms] NOT 
"humans"[MeSH Terms])) 
 
8.2 Search results and study selection 
Table 7 Search results and study selection (01.07.2007-20.04.2012) 
References Excl./Inc
l. 
1. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of 
a randomised, controlled trial. 
Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, Wu H, Wang G, Shi Q, Andhivarothai N, Anderson J, 
Pangan AL. 
Ann Rheum Dis. 2013 Mar 8. [Epub ahead of print] 
RCT 
2. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-
blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese 
population. 
Li ZH, Zhang Y, Wang J, Shi ZJ. 
Eur J Orthop Surg Traumatol. 2012 Jun 29. [Epub ahead of print] 
Not RCT 
3. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: 
a randomized, prospective, long-term, follow-up study. 
Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C. 
Biologics. 2013;7:1-6. doi: 10.2147/BTT.S31474. Epub 2013 Jan 4. 
 
 
4. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment 
studies. 
van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS. 
Ann Rheum Dis. 2012 Dec 22. [Epub ahead of print] 
Not RCT 
5. Adalimumab: in non-radiographic axial spondyloarthritis. 
Burness CB, Deeks ED. 
Drugs. 2012 Dec 24;72(18):2385-95. doi: 10.2165/11470250-000000000-00000. 
Not RCT 
6. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial 
spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. 
Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, 
Freundlich B, Rudwaleit M, Sieper J. 
Ann Rheum Dis. 2012 Nov 21. [Epub ahead of print] 
Not RCT 
ESTHE
R 
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References Excl./Inc
l. 
7. Drug Class Review: Targeted Immune Modulators: Final Update 3 Report [Internet]. 
Thaler KJ, Gartlehner G, Kien C, Van Noord MG, Thakurta S, Wines RCM, Hansen RA, 
McDonagh MS. 
Portland (OR): Oregon Health &amp; Science University; 2012 Mar. 
Not RCT 
8. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of 
etanercept. 
Deng X, Zhang J, Zhang J, Huang F. 
Rheumatol Int. 2012 Nov 11. [Epub ahead of print] 
Not RCT 
 
9. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis 
patients without ankylosing spondylitis or psoriatic arthritis. 
Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, Tak PP, Baeten DL. 
Ann Rheum Dis. 2012 Nov 8. [Epub ahead of print] 
other 
disease 
10. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile 
onset ankylosing spondylitis (JoAS): significant short term improvement. 
Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte 
M, Ganser G, Trauzeddel R, Huppertz HI. 
Arthritis Res Ther. 2012 Oct 24;14(5):R230. [Epub ahead of print] 
RCT 
12-17 
age 
11. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of 
golimumab in ankylosing spondylitis (GO-RAISE). 
van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B. 
Rheumatology (Oxford). 2013 Feb;52(2):321-5. doi: 10.1093/rheumatology/kes251. Epub 2012 Sep 
28. 
post-hoc 
analysis 
of RCT 
GO 
RAISE 
12. Markers of inflammation and bone remodelling associated with improvement in clinical response 
measures in psoriatic arthritis patients treated with golimumab. 
Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, 
Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A. 
Ann Rheum Dis. 2013 Jan;72(1):83-8. doi: 10.1136/annrheumdis-2012-201697. Epub 2012 Sep 12. 
RCT 
Other 
disease 
GO-
REVEA
L 
analysis 
13. MRI inflammation and its relation with measures of clinical disease activity and different 
treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor 
inhibitor. 
Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. 
Ann Rheum Dis. 2012 Dec;71(12):2002-5. doi: 10.1136/annrheumdis-2012-201999. Epub 2012 Aug 
21. 
Not RCT 
14. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 
vaccine in inflammatory arthritis patients. 
França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, 
Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E. 
Rheumatology (Oxford). 2012 Nov;51(11):2091-8. doi: 10.1093/rheumatology/kes202. Epub 2012 
Aug 20. 
Not RCT 
15. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty 
deposition in lumbar spine in active ankylosing spondylitis. 
Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, Wei Q, Zhang YL, Li T, Jin O, Huang J, Pan Y, Wu Y, 
Deng X, Gu J. 
Int J Rheum Dis. 2012 Aug;15(4):358-65. doi: 10.1111/j.1756-185X.2012.01734.x. Epub 2012 May 
23. Erratum in: Int J Rheum Dis. 2012 Dec;15(6):564. 
RCT 
not the 
examine
d end-
point 
16. [The efficacy of etanercept in enthesitis in ankylosing spondylitis and an evaluation method for 
enthesitis]. 
Zhang J, Huang F, Zhang JL, Zhang H, Zhang YM. 
Zhonghua Nei Ke Za Zhi. 2012 May;51(5):376-9. Chinese. 
RCT 
Chinise 
6 
week+6 
week 
open 
label 
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References Excl./Inc
l. 
17. Efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing 
spondylitis stabilized by tumor necrosis factor inhibitor therapy. 
So MW, Heo HM, Koo BS, Kim YG, Lee CK, Yoo B. 
J Rheumatol. 2012 Sep;39(9):1854-8. doi: 10.3899/jrheum.120137. Epub 2012 Aug 1. 
RCT 
other 
treatmen
t 
18. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated 
with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. 
Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, Xu S, Rahman MU. 
Arthritis Care Res (Hoboken). 2013 Feb;65(2):309-13. doi: 10.1002/acr.21788. 
Not RCT 
19. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: 
results of a randomised placebo-controlled trial (ABILITY-1). 
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, 
Pangan AL. 
Ann Rheum Dis. 2012 Jul 7. [Epub ahead of print] 
RCT 
ABILIT
Y-1 
with 
non-
radiogra
phic 
axial 
spondylo
arthritis 
 
20. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in 
patients treated with etanercept or sulphasalazine in the ASCEND trial. 
van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS. 
Rheumatology (Oxford). 2012 Oct;51(10):1894-905. Epub 2012 Jul 6. 
RCT 
Post-hoc 
analysis 
ASCEN
D 
 
21. Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of 
Canada Spine and Sacroiliac Joint Magnetic Resonance Imaging Indices for Ankylosing Spondylitis. 
Maksymowych WP, Lambert RG, Brown LS, Pangan AL. 
J Rheumatol. 2012 Aug;39(8):1666-74. doi: 10.3899/jrheum.120131. Epub 2012 Jul 1. 
RCT 
post-
hoc 
Lambe
rt 2007 
22. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes 
including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a 
Randomized, Placebo-controlled Study (GO-REVEAL). 
Kavanaugh A, Mease P. 
J Rheumatol Suppl. 2012 Jul;89:90-3. doi: 10.3899/jrheum.120254. 
extentio
n of 
GO-
REVEA
L  
Not the 
disease 
23. Adalimumab in psoriatic arthritis. 
Salvarani C, Pipitone N, Catanoso M, Chiarolanza I, Boiardi L, Caruso A, Pazzola G, Macchioni P, 
Di Lernia V, Albertini G. 
J Rheumatol Suppl. 2012 Jul;89:77-81. doi: 10.3899/jrheum.120251. Review. 
Not RCT 
24. Etanercept in psoriatic arthritis. 
Spadaro A, Lubrano E, Ferrara N, Scarpa R. 
J Rheumatol Suppl. 2012 Jul;89:74-6. doi: 10.3899/jrheum.120250. Review. 
Not RCT 
25. Infliximab in psoriatic arthritis. 
Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E. 
J Rheumatol Suppl. 2012 Jul;89:71-3. doi: 10.3899/jrheum.120249. Review. 
Not RCT 
26. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index 
in a randomized placebo-controlled study. 
van der Heijde D, Deodhar A, Inman RD, Braun J, Hsu B, Mack M. 
Arthritis Care Res (Hoboken). 2012 Dec;64(12):1919-22. doi: 10.1002/acr.21771. 
methodo
logical 
GO-
RAISE 
27. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 
12-week open-label extension of the SPINE study. 
Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I. 
Rheumatology (Oxford). 2012 Sep;51(9):1687-96. doi: 10.1093/rheumatology/kes125. Epub 2012 
May 30. 
extentio
n of 
SPINE 
  
72 Appendices 
References Excl./Inc
l. 
28. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients 
treated with anti-tumor necrosis factor agents. 
Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. 
J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11. 
Not RCT 
29. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: 
evidence for a window of opportunity in disease modification. 
Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. 
Ann Rheum Dis. 2013 Jan;72(1):23-8. doi: 10.1136/annrheumdis-2011-200859. Epub 2012 May 5. 
Not RCT 
30. The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis. 
Gensler L, Inman R, Deodhar A. 
Am J Med Sci. 2012 May;343(5):360-3. doi: 10.1097/MAJ.0b013e318251406c. Review. 
Not RCT 
31. Golimumab for the treatment of psoriatic arthritis. 
Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N. 
Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review. 
Not RCT 
32.Efficacy of low-dose etanercept (25 mg/week): how much do we know? 
Berthelot JM. 
Joint Bone Spine. 2012 Jul;79(4):335-7. doi: 10.1016/j.jbspin.2012.02.008. Epub 2012 Apr 4. No 
abstract available. 
Not RCT 
33. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus 
sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. 
Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, Weiß A, Djacenko S, 
Burmester GR, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J. 
Ann Rheum Dis. 2012 Jul;71(7):1212-5. doi: 10.1136/annrheumdis-2011-201010. Epub 2012 Mar 
22. 
Not RCT 
ESTHE
R 
follow 
up 
34. Update of the literature review on treatment with biologics as a basis for the first update of 
the ASAS/EULAR management recommendations of ankylosing spondylitis. 
Baraliakos X, van den Berg R, Braun J, van der Heijde D. 
Rheumatology (Oxford). 2012 Aug;51(8):1378-87. doi: 10.1093/rheumatology/kes026. Epub 
2012 Mar 16. 
Reveiw 
35. Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has 
changed clinical practice. 
Atzeni F, Sarzi-Puttini P. 
Expert Rev Clin Immunol. 2012 Mar;8(3):213-22. doi: 10.1586/eci.12.6. 
Not RCT 
36. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from 
a phase III, randomized, placebo-controlled trial. 
Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, 
Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A. 
Arthritis Rheum. 2012 Aug;64(8):2504-17. doi: 10.1002/art.34436. 
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261. [The role of biological agents in the treatment of psoriatic arthritis, literature review]. 
Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L. 
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262. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis 
through 1 year of treatment: results from the IMPACT 2 trial. 
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Simpson D, Scott LJ. 
Drugs. 2006;66(11):1487-96; discussion 1497-9. 
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Not RCT 
287. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective. 
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295. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in 
Canada. 
Kobelt G, Andlin-Sobocki P, Maksymowych WP. 
J Rheumatol. 2006 Apr;33(4):732-40. 
Not RCT 
cost-eff. 
296. Orbital cellulitis in a patient receiving infliximab for Ankylosing spondylitis. 
Roos JC, Ostor AJ. 
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[No authors listed] 
Drug Ther Bull. 2006 Jan;44(1):1-5. Review. 
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RCT 
Other 
disease 
  
94 Appendices 
References Excl./Inc
l. 
310. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in 
patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor 
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Open 
label ext. 
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8.3 Quality assessment of included studies; detailed description of Jadad 
score 
Calculating Jadad score is based on a three-point questionnaire published by Jadad et al.
32
. 
Each question can be answered with either a yes or a no. Each yes scores one point, each no 
zero points. The questions were: 
1. Was the study described as randomized? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and dropouts? 
To receive the corresponding point, an article should describe the number of withdrawals and 
dropouts, in each of the study groups, and the underlying reasons.  
Additional points were given if: 
 The method of randomisation was described in the paper, and that method was 
appropriate. 
 The method of blinding was described, and it was appropriate. 
Points would however be deducted if: 
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 The method of randomisation was described, but was inappropriate. 
 The method of blinding was described, but was inappropriate. 
A paper reporting a clinical trial could therefore receive a Jadad score of between zero and 
five. 
8.4 Description of mixed treatment models and WinBUGS codes 
All MTC models used the odds ratio as the measure of relative treatment effect and assumed 
that treatment effects on the odds-ratio scale were multiplicative and exchangeable between 
trials. Each model was run with 3 chains and 10,000 burn-in iterations in order to limit the 
influence of the initial values on the simulated posterior distribution. A further 20,000 MCMC 
iterations were run, and the sampled values were used to estimate posterior means and 95% 
credibility intervals (CrIs). Credibility intervals are the Bayesian equivalent of classical 
confidence intervals.  
Convergence was assessed based on Brooks-Gelman-Rubin (BGR) plot. The accuracy of the 
posterior estimates was done by calculating the Monte Carlo error for each parameter. As a 
rule of thumb, the Monte Carlo error for each parameter of interest is less than about 5% of 
the sample standard deviation. The overall residual deviance was compared to the number of 
independent data points to check if the model fit the data satisfactory. For a Binomial 
likelihood, each trial arm contributes 1 independent data point.  
Differences between treatments were considered significantly significant at the 0.05 level if 
the 95% CrIs around the odds ratio did not cross 1. 
WinBugs program code 
 
 
 
# Binomial likelihood, logit link 
# Fixed effects model  
model{                          # *** PROGRAM STARTS 
for(i in 1:ns){                 # LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)      # vague priors for all trial baselines 
    for (k in 1:na[i])  {       # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
# model for linear predictor 
        logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] 
# expected value of the numerators  
        rhat[i,k] <- p[i,k] * n[i,k] 
#Deviance contribution 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
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             +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-
rhat[i,k]))) 
      } 
# summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]]) 
     }    
totresdev <- sum(resdev[])      # Total Residual Deviance 
d[1]<-0    # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
 
     
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2 
for (c in 1:(nt-1)) { 
for (k in (c+1):nt) { 
or[c,k] <- exp(d[k] - d[c]) 
lor[c,k] <- (d[k]-d[c]) 
} 
} 
# ranking on relative scale 
for (k in 1:nt) { 
 rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
#rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
}        
}                                          # *** PROGRAM ENDS 
 
 
8.5 Detailed description of RCTs included 
Table 8 Braun 2002, infliximab 
Examination randomised controlled multicentre trial 
Number of patients 70 
Inclusion criteria - fulfilled modified New York criteria for ankylosing spondylitis 
- had severe active disease that was defined by a Bath ankylosing spondylitis 
disease activity index (BASDAI) of 4 or greater, and spinal pain of 4 or 
greater on a 10-cm visual analogue scale 
Exclusion criteria - had active tuberculosis within the previous 3 years, specific changes in the 
radiograph of the chest at baseline, serious infections within the previous 2 
months 
- history of lymphoproliferative disease or other malignant diseases in the 
past 5 years 
- had signs or symptoms of severe renal, hepatic, haematological, 
gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral 
disease 
Therapy - intravenous infliximab (5 mg/kg) at week 0, 2 and 6 
- placebo at weeks 0, 2, and 6 
Co-therapies DMARDs and oral corticosteroids were withdrawn min. 4 weeks 
before screening, patients were allowed to take NSAIDs, but the dose could 
not be increased over the baseline value (the dose could be reduced and such 
reductions were recorded) 
Follow-up time 12 week 
Primary endpoint improvement of disease activity by 50% between baseline and week 12, 
measured by BASDAI 
Secondary endpoints - improvements in visual analogue score for spinal pain, BASFI, BASMI, 
SF36, the working group response criteria, concentration of C-reactive 
protein in serum, and erythrocyte sedimentation rate 
JADAD score 5  
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Table 9 Gorman 2002, etanercept 
Examination a randomized, double-blind, placebo-controlled trial 
Number of patients 40 
Inclusion criteria - had to meet the modified New York clinical criteria for definite ankylosing 
spondylitis 
- have evidence of active spondylitis despite accepted treatments, and be at 
least 18 years old 
- active spondylitis was defined as the presence of inflammatory back pain 
(stiffness and pain that worsened with rest and improved with exercise), 
morning stiffness for at least 45 minutes, and at least moderate disease 
activity as assessed by the patient and the physician 
Exclusion criteria - had a spondylitis other than ankylosing spondylitis, clinical or radiographic 
evidence of complete spinal ankylosis 
- a history of recurrent infections or cancer, or a serious liver, renal, 
hematologic, or neurologic disorder 
Therapy - twice-weekly subcutaneous injections of etanercept (25 mg) for four 
months 
- placebo for four months 
Co-therapies Px continued previous Rx regimens (of NSAIDs and/or DMARDS: 
prednisone, SSZ, MTX, azathioprine, gold) 
Follow-up time 4 months 
Primary endpoint 20 percent or greater improvement in at least three of five measures of 
disease activity, as recommended by the Assessments in Ankylosing 
Spondylitis Working Group 
(duration of morning stiffness, degree of nocturnal spinal pain, the Bath 
Ankylosing Spondylitis Functional Index, the patient’s global assessment of 
disease activity, and the score for joint swelling), one of which was required 
to be duration of morning 
stiffness or degree of nocturnal spinal pain, with no worsening 
in any of the measures 
Secondary endpoints the physician’s global assessment of disease activity, measures of spinal 
mobility, the scores for enthesitis and peripheral-joint tenderness, the 
erythrocyte sedimentation rate, and the C-reactive protein level 
JADAD score 5 
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Table 10 Calin 2004, etanercept 
Examination double blind, randomised, placebo controlled study 
Number of patients 84 
Inclusion criteria - aged 18–70 years with active AS  
(AS was diagnosed using the modified New York criteria.  Active disease 
was diagnosed if the patient had an average score >30 for spinal 
inflammation and a score >30 on at least two of the other three domains) 
Exclusion criteria - had complete ankylosis (fusion) of the spine 
- previously used TNFa inhibitors, including etanercept 
- used DMARDs other than hydroxychloroquine, sulfasalazine, or 
methotrexate within 4 weeks of baseline 
- used multiple NSAIDs 
- used > 10 mg prednisone daily 
- or changed doses of NSAIDs or prednisone within 2 weeks of baseline 
Therapy - 25 mg injections of etanercept twice weekly for 12 weeks 
- placebo twice weekly for 12 weeks 
Co-therapies Physiotherapy (where existing programmes, continued); concomitant use of 
NSAIDs, DMARDs, corticosteriods permitted (participants stratified by 
baseline DMARD use and then randomised, changes in 
or multiple NSAID use exclusion criteria 
Follow-up time 12 week 
Primary endpoint an improvement of at least 20% in patient reported symptoms, based on the 
multicomponent Assessments in Ankylosing Spondylitis (ASAS) response 
criteria (ASAS 20) 
Secondary endpoints ASAS 50 and ASAS 70 responses and improved scores on individual 
components of ASAS, the Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI), acute phase reactants, and spinal mobility tests 
JADAD score 5 
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Table 11 Davis 2003, etanercept 
Examination multicenter, randomized, placebocontrolled, double-blind trial 
Number of patients 277 
Inclusion criteria - men or women ages 18 to 70 years  
- satisfied the modified New York criteria for AS  
- had active AS 
Exclusion criteria - had complete ankylosis (fusion) of the spine based on radiographic 
assessment 
- had previously received TNF inhibitor therapy 
- had a serious infection (associated with hospitalization or intravenous 
antibiotics) within 4 weeks before screening, or were pregnant 
Therapy - etanercept 25 mg subcutaneously twice weekly for 24 weeks 
- placebo subcutaneously twice weekly for 24 weeks 
Co-therapies Px continued stable Rx regimens of HCQ, SSZ, MTX, NSAIDs or 
prednisone; standard doses of analgesics (paracetamol, codeine, 
hydrocodone, oxycodone, tramadol) permitted 
Follow-up time 24 week 
Primary endpoint the percentages of patients achieving the Assessments in Ankylosing 
Spondylitis 20% response (ASAS20) at weeks 12 and 24 
Secondary endpoints achievement of the ASAS50 and ASAS70 
JADAD score 5 
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Table 12 Heijde 2005, ASSERT, infliximab 
Examination multicenter, randomized, placebo-controlled study 
Number of patients 279 
Inclusion criteria - having AS (according to the modified New York criteria) for at least 3 
months prior to screening, with a Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) score of ≥ 4 (range 0–10), and with a spinal pain 
assessment score of ≥ 4 on a visual analog scale (VAS; range 0–10 cm) 
- have a normal chest radiograph within 3 months prior to randomization and 
either a negative purified protein derivative (PPD) skin test result for latent 
tuberculosis (in the US and Canada) or adequate screening with documented 
negative results for latent tuberculosis using local guidelines for high-risk or 
immunocompromised patients (in Europe) 
Exclusion criteria - had any of the following diagnoses or medical history: total ankylosis of 
the spine (defined by syndesmophytes present on the lateral views of spinal 
radiographs at all intervertebral levels 
from T6 through S1), any other inflammatory rheumatic disease, 
fibromyalgia, a serious infection within 2 months prior 
to randomization, tuberculosis (active or latent) or recent contact with a 
person with active tuberculosis, an opportunistic 
infection within 6 months of screening, hepatitis, human immunodeficiency 
virus, a transplanted organ, malignancy, multiple sclerosis, or congestive 
heart failure 
- receive sulfasalazine or methotrexate within 2 weeks prior to screening, 
systemic corticosteroids within 1 month prior to screening, anti-TNF therapy 
other than infliximab within 3 months prior to screening, infliximab at any 
time prior to screening, DMARDs other than sulfasalazine or methotrexate 
within 6 months prior to screening, or cytotoxic drugs within 12 months 
prior to screening 
Therapy infusions of placebo at weeks 0, 2, 6, 12, and 18 
infusions of 5 mg/kg infliximab at weeks 0, 2, 6, 12, and 18 
Co-therapies Permitted: NSAIDs (paracetamol, tramadol) stable doses; not permitted: 
SSZ, MTX <2 weeks*, DMARDs (other than SSZ 
or MTX) <6 months*, systemic corticosteroids <1 month, anti-TNF (other 
than infliximab) <3 months*, cytotoxic drugs <12 months* (*prior to 
screening) 
Follow-up time 24 week 
Primary endpoint the proportion of patients with a 20% improvement response according to the 
ASAS International Working Group criteria 
(ASAS20 responders) at week 24 
Secondary endpoints - ASAS40 response (40% improvement from baseline and an absolute 
improvement of at least 2 units [on a scale of 0–10] in at least 3 of the 4 
assessment domains defined in the ASAS20 response criteria, with no 
deterioration from baseline in the potential remaining assessment domain) 
- ASAS partial remission (an absolute score of <2 in each of the above 4 
ASAS assessment domains), and 20% improvement in at least 5 of the 
following 6 ASAS assessment domains (an ASAS 5 of 6 response): spinal 
pain, patient’s global assessment, function according to the BASFI, morning 
stiffness, CRP level, and the Bath Ankylosing Spondylitis Metrology Index 
(BASMI) score 
- disease activity, physical function, range-of-motion assessments, other 
musculoskeletal assessments, and quality of life 
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Table 13 Heijde, 2006, adalimumab ATLAS 
Examination multicenter, randomized, double-blind, placebo-controlled study 
Number of patients 315 
Inclusion criteria - at least 18 years of age and were classified as having definite AS based on 
the modified New York criteria  
- had active disease, which was defined as fulfillment of at least 2 of the 
following 3 criteria: a Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) score ≥ 4, a total back pain score ≥ 4 by visual analog scale 
(VAS; 0–10 cm), or a duration of morning stiffness ≥ 1 hour 
- patients with stable and well-controlled psoriasis, uveitis, inflammatory 
bowel disease (i.e., ulcerative colitis, Crohn’s disease), and reactive arthritis 
- inadequate response or intolerance to 1 or more nonsteroidal 
antiinflammatory drugs (NSAIDs)  
Exclusion criteria - had previously received anti-TNF therapy, cyclosporine, azathioprine, or 
DMARDs (other than the medications and dosages listed above) at any time 
and patients who had received intraarticular injection(s) with corticosteroids 
within 4 weeks prior to baseline  
- clinically active TB were 
- a history of any recent infections requiring antibiotic treatment; hepatitis or 
human immunodeficiency virus; a significant history of cardiac, renal, 
neurologic, psychiatric, endocrinologic, metabolic, or hepatic disease; and a 
history of demyelinating disease or multiple sclerosis  
- a history of cancer or lymphoproliferative disease other than a 
successfully treated nonmetastatic squamous cell or basal cell carcinoma 
and/or localized carcinoma in situ of the cervix 
Therapy - subcutaneous injection of adalimumab, 40 mg every other week 
- placebo for 24 weeks 
Co-therapies DMARDs (corticosteroids, MTX, SSZ or HCQ) should not have been 
initiated or increased before week 36; corticosteroids, could have 
been decreased, or stopped after week 24 at investigator’s discretion. 
MTX, SSZ or HCQ should not have been decreased before week 36 
Follow-up time 24 week 
Primary endpoint the percentage of patients with a 20% response according to the 
ASsessment in Ankylosing Spondylitis International Working Group criteria 
for improvement (ASAS20) at week 12 
Secondary endpoints ASAS20 at week 24 and multiple measures of disease activity, spinal 
mobility, and function, as well as ASAS partial remission 
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Table 14 Maksymowich 2005 Canadian AS, Lambert, 2007, adalimumab 
Examination multicenter, randomized, double-blind, placebo-controlled study 
Number of patients 82 
Inclusion criteria - adults (≥ 18 years of age) diagnosed as having AS as defined by the 
modified New York criteria  
- had been treated unsuccessfully (nonresponse or lack of tolerance) with ≥ 1 
nonsteroidal antiinflammatory drugs (NSAIDs) 
- had failed to respond to ≥ 1 disease-modifying antirheumatic drugs (e.g., 
methotrexate, sulfasalazine)  
- active AS at baseline was defined by fulfillment of 2 of the following 3 
criteria: a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 
score ≥ 4, total back pain visual analog scale score ≥ 40, or morning stiffness 
of ≥ 1 hour in duration 
Exclusion criteria - 
Therapy - 40 mg adalimumab every other week during the initial 24-week double-
blind period 
- placebo every other week during the initial 24-week double-blind period 
Co-therapies DMARDs (corticosteroids, MTX, SSZ or HCQ) should not have been 
initiated or increased before week 36; corticosteroids, could have 
been decreased, or stopped after week 24 at investigator’s discretion. 
MTX, SSZ or HCQ should not have been decreased before week 36 
Follow-up time 24 week 
Primary endpoint ASAS20 response at week 12 
Secondary endpoints SPARCC scores 
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Table 15 Heijde 2006, etanercept 
Examination randomised, double-blind, placebocontrolled, multicentre study 
Number of patients 356 
Inclusion criteria - aged 18–70 years, with active ankylosing spondylitis based on the 
Modified New York Criteria for ankylosing spondylitis  
- active ankylosing spondylitis was defined by an average visual analogue 
scale (VAS) score ≥ 30 for duration and intensity of morning stiffness and 
two or more of the following: patient global assessment of disease activity 
VAS score ≥ 30; mean of 
nocturnal and total pain VAS scores ≥ 30; or Bath Ankylosing 
Spondylitis Functional Index ≥ 30 (all scores on a scale of 0-100) 
Exclusion criteria - previously treated with TNFa inhibitors, including etanercept or other 
biological agents, or disease-modifying antirheumatic drugs (other than 
hydrochloroquine, sulfasalazine and methotrexate) less than 4 weeks before 
baseline 
- complete ankylosis (fusion) of the spine based on radiographic 
assessment and concurrent medical events, such as uncontrolled 
hypertension, unstable angina pectoris, congestive heart failure, severe 
pulmonary disease, cancer, demyelinating diseases of the central nervous 
system and serious infections 
Therapy - etanercept 50 mg once weekly 
- etanercept 25 mg twice weekly 
- placebo 
Co-therapies  
Follow-up time 12 week 
Primary endpoint the proportion of patients achieving a response at week 12 based on the 
Assessment in Ankylosing Spondylitis Working Group criteria (ASAS 20) 
Secondary endpoints - the proportion of responders based on ASAS 40 and ASAS 5/6 criteria at 
all time points 
- ASAS 40 is based on the same domains as ASAS 20, but requires at least a 
40% improvement and 20 units in at least three of the four domains and no 
worsening in the remaining domain.20 ASAS 5/6 responders are defined as 
patients showing >20% improvement in five of six domains: the four 
domains in ASAS 20 and C reactive protein (CRP) levels, and spinal 
mobility (modified Schober’s test) patient and physician global assessments 
of disease activity, nocturnal and total back pain assessments, Bath 
Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis 
Disease Activities Index 
(BASDAI), patients achieving partial remission, time to partial 
remission, spinal mobility (modified Schober’s test, chest expansion 
measurement and occiput-to-wall distance), joint assessment (70 joints) and 
serum CRP 
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Table 16. Barkham 2010, etanercept 
Examination randomised double-blind placebo-controlled study 
Number of patients 40 
Inclusion criteria - had a definite diagnosis of AS by modified New York Criteria and active 
disease as defined by two out of three of Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) ≥40 (0–100), visual analogue scale (VAS) 
pain ≥40 (0–100), early morning stiffness ≥45 min 
- all were in work but were work unstable (AS-WIS score >10) 
Exclusion criteria past or current tuberculosis, congestive heart disease or treatment with 
glucocorticoids in the previous month 
Therapy - 25 mg etanercept twice weekly for 12 weeks 
- placebo twice weekly for 12 weeks 
Co-therapies - 
Follow-up time 12 week 
Primary endpoint - change in AS-WIS at week 12 
Secondary endpoints - clinical outcomes and gait parameters: assessments of disease activity 
(BASDAI), quality of life, functional ability (Bath Ankylosing Spondylitis 
Functional Index (BASFI), gait parameters using an electronic walkway and 
disability (Disability Index of Stanford Health Assessment Questionnaire 
(HAQ-DI) 
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Table 17. Doudogas 2011, SPINE study, etanercept 
Examination multicentre randomised double-blind placebo-controlled trial 
Number of patients 82 
Inclusion criteria - men and women aged 18–70 years were eligible if they had a current 
diagnosis of AS as defined by the modified New York criteria 
- patients also had to have baseline pain with axial involvement of the overall 
level of AS neck, back or hip for a score ≥30 on a 0–100 mm visual analogue 
scale 
- had to have an active refractory disease defined by a score ≥40 on the Bath 
AS Disease Activity Index (BASDAI) (0–100) despite optimal non-steroidal 
anti-inflammatory drug (NSAID) treatment (at least two NSAIDs at the 
maximal tolerated dose for >3 months and according to the opinion of the 
investigator) 
Exclusion criteria - had been previously exposed to a TNF inhibitor, if the NSAID dose had 
changed within 2 weeks of baseline evaluation and if the dose of 
concomitant conventional disease-modifying antirheumatic drug, if taken, 
had changed within 4 weeks of baseline evaluation 
- had significant concurrent medical disorders (eg, cancer or history of 
cancer, serious infection) and/or abnormal laboratory test results 
Therapy - ETN 50 mg once weekly 
- placebo 
Co-therapies - during the 12 weeks of the study the dose of concomitant NSAIDs and any 
concomitant DMARD had to remain stable 
- in case of a painful episode during the study, analgesics such as 
paracetamol, with or without codeine or dextropropoxyphen, could be used 
Follow-up time 12 week 
Primary endpoint - BASDAI between randomisation and week 12 
Secondary endpoints - ASAS20, ASAS40, ASAS5/6, ASAS partial remission, and improvement 
in BASDAI of at least 50% (BASDAI50), improvement in AS-DAS and AS-
DAS status 
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Table 18. Inman, 2008, GO-RAISE, golimumab 
Examination randomized, double-blind, placebo-controlled, phase III trial 
Number of patients 356 
Inclusion criteria - had AS, a spinal pain assessment score of ≥ 4 on a visual analog scale 
(VAS; 0–10-cm scale), and an inadequate response to current or previous 
nonsteroidal antiinflammatory drugs (NSAIDs) or disease-modifying 
antirheumatic drugs 
- normal results of a chest radiograph within 3 months before randomization 
and to have undergone screening for latent tuberculosis (TB) using a purified 
protein derivative skin test and the QuantiFERON TB Gold test 
- patients who were receiving NSAIDs had to have received continuous 
therapy for 3 months at the highest recommended doses or had to have been 
unable to receive a full 3-month course of full-dose NSAID therapy because 
of intolerance, toxicity, or contraindications 
- patients in whom latent TB was discovered were required to initiate therapy 
for TB prior to or simultaneously with the first dose of the study agent 
Exclusion criteria - had any of the following: complete ankylosis of the spine, any other 
inflammatory rheumatic disease, a serious infection within 2 months before 
randomization, active or latent TB or positive 
results of a tuberculin skin test before screening or recent contact with a 
person with active TB, an opportunistic infection 
within 6 months of screening, hepatitis, human immunodeficiency virus, a 
transplanted organ, malignancy, multiple sclerosis, or congestive heart 
failure 
Therapy - golimumab 50 mg 
- golimumab 100 mg 
- placebo 
Co-therapies - patients were allowed to continue concurrent treatment with methotrexate 
(MTX), sulfasalazine, hydroxychloroquine, corticosteroids, and NSAIDs at 
stable doses during the study 
Follow-up time 24 week 
Primary endpoint proportion of patients with at least 20% improvement in the ASsessment in 
AS (ASAS20) criteria at week 14 
Secondary endpoints - ASAS 40% improvement (ASAS40), ASAS partial remission, and 20% 
improvement in 5 of 6 ASAS domains (ASAS5/6) 
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Table 19. Huang 2013, adalimumab 
Examination placebo-controlled, double-blind, randomised, phase III trial 
Number of patients 344 
Inclusion criteria - 18 and 65 years of age, fulfilled modified New York Criteria for AS, had 
active disease (as defined by ≥2 of the following: 
Bath AS Disease Activity Index (BASDAI) ≥4 cm; total back pain on a 
visual analogue scale (VAS) ≥4 cm; and ≥1 hour of morning stiffness), and 
had an inadequate response or were intolerant to ≥1 NSAID 
Exclusion criteria - patients with latent tuberculosis (TB) based on results of a positive purified 
protein derivative (PPD) test and chest radiograph had either completed or 
were receiving anti-TB therapy; patients with active, untreated TB 
- if they had total spinal ankylosis (bamboo spine); unstable extra-articular 
manifestations (eg, psoriasis, uveitis, inflammatory bowel disease); surgery 
involving the spine or joints within the previous 2 months; intra-articular or 
spinal/paraspinal corticosteroid injections within the previous 28 days; 
positive serology for HIV antibody, hepatitis B surface antibody or hepatitis 
C virus antibody; recent infection requiring anti-infectives; listeriosis; 
histoplasmosis; immunodeficiency syndrome; or chronic recurring infections 
- moderate to severe congestive heart failure, recent cerebrovascular 
accident, central nervous system demyelinating disease, or history of 
malignancy 
- prior exposure to TNF-α inhibitors, natalizumab or efalizumab 
at any time, or use of traditional Chinese medicines within 28 days of 
baseline 
Therapy - adalimumab 40 mg subcutaneously every other week (EOW) for 12 weeks 
- placebo subcutaneously every other week (EOW) for 12 weeks 
Co-therapies - concomitant use of methotrexate (≤25 mg/week), sulfasalazine (≤3 g/day), 
prednisone (≤10 mg/day), NSAIDs and/or analgesics was allowed but dose 
adjustments, induction and/or discontinuation of these therapies were only 
permitted during the open-label period 
Follow-up time 12 week 
Primary endpoint - the percentage of patients meeting the Assessment in Spondyloarthritis 
International Society (ASAS20) response criteria at week 12 
Secondary endpoints - at weeks 12 and 24 were the percentage of patients achieving the following 
outcome measures: ASAS40, ASAS5/6, high-sensitivity C-reactive protein 
(hs-CRP); percentage of patients 
achieving ASAS partial remission, the percentage of patients achieving at 
least 50% improvement in the BASDAI score 
(BASDAI50) 
- disease activity, pain and spinal mobility by measuring changes from 
baseline in PTGA (VAS), total back pain (VAS), inflammation/morning 
stiffness, BASDAI, physician’s global assessment of disease activity (VAS), 
nocturnal pain (VAS), patient’s global assessment of pain (VAS), tender 
joint count, swollen joint count, Maastricht AS Enthesitis Score (MASES), 
BASMI-linear and chest expansion 
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8.6 Detailed results from classical direct meta-analysis 
Note: In some of the cases exact numbers were not presented in the studies, only graphs. In 
the following cases the numbers were read from graphs: 
 Braun 2002: ASAS20, ASAS partial remission at week 12 
 Heijde 2005 ASSERT: ASAS20, ASAS 40 at week 12 
 Heijde 2006 ATLAS: ASAS20 at week 24 
 Inman 2008: ASAS40, ASAS5/6, ASAS partial remission at week 12 and 24 
 
Forest plot of comparison: Efficacy of biologicals – ASAS20 at week 12 
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Forest plot of comparison: Efficacy of biologicals – ASAS40 at week 12 
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Forest plot of comparison: Efficacy of biologicals – ASAS5/6 at week 12 
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Forest plot of comparison: Efficacy of biologicals – ASAS Partial remission at week 12 
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Forest plot of comparison: Efficacy of biologicals – BASDAI 50 at week 12 
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Forest plot of comparison: Efficacy of biologicals – ASAS20 at week 24 
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Forest plot of comparison: Efficacy of biologicals – ASAS40 at week 24 
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Forest plot of comparison: Efficacy of biologicals – ASAS5/6 at week 24 
 
 
  
116 Appendices 
Forest plot of comparison: Efficacy of biologicals – ASAS Partial remission at week 24 
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Forest plot of comparison: Efficacy of biologicals – BASDAI 50 at week 24 
 
 
  
118 Appendices 
Forest plot of comparison: Safety of biologicals – Adverse events 
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Forest plot of comparison: Safety of biologicals – Serious adverse events 
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Forest plot of comparison: Safety of biologicals – Adverse events leading to 
discontionuation of therapy 
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Forest plot of comparison: Safety of biologicals – Infections 
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Forest plot of comparison: Safety of biologicals – Serious infections 
 
 
  
123 Appendices 
Forest plot of comparison: Safety of biologicals – Injection stie reaction 
 
 
 
8.7 Literature search strategies for cost-utility articles 
Ovid MEDLINE(R) 1946 to Present with Daily Update, 11th April, 2013 
Search strategy (number of hits): 
1     economics/ (26558) 
2     exp "Costs and Cost Analysis"/ (170666) 
3     VALUE OF LIFE/ (5308) 
4     economics, dental/ (1855) 
5     exp economics, hospital/ (18518) 
6     economics, medical/ (8493) 
7     economics, nursing/ (3870) 
8     economics, pharmaceutical/ (2417) 
9     (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom$).ti,ab. 
(139598) 
10     (expenditure$ not energy).ti,ab. (15965) 
11     (value adj1 money).ti,ab. (19) 
12     budget$.ti,ab. (16084) 
13     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (316033) 
14     ((energy or oxygen) adj cost).ti,ab. (2486) 
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15     (metabolic adj cost).ti,ab. (687) 
16     ((energy or oxygen) adj expenditure).ti,ab. (14820) 
17     14 or 15 or 16 (17335) 
18     13 not 17 (315238) 
19     letter.pt. (767716) 
20     editorial.pt. (312781) 
21     historical article.pt. (291220) 
22     19 or 20 or 21 (1357819) 
23     18 not 22 (293153) 
24     Animals/ (5083309) 
25     Humans/ (12745180) 
26     24 NOT (24 AND 25) {Including Related Terms} (14679) 
27     23 not 26 (292897) 
28     Ankylosing, Spondylitis/ (11149) 
29     (etanercept or enbrel or tnfr-fc).ti,ab,rn. (4599) 
30     (infliximab or remicade).ti,ab,rn. (7406) 
31     (adalimumab or humira or D2E7).ti,ab,rn. (2721) 
32     (golimumab or simponi).ti,ab,rn. (197) 
33     29 or 30 or 31 or 32 (11054) 
34     27 and 28 and 33 (31) 
35     limit 34 to yr="2011 -Current" (7) 
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <, 23rd April, 2012> 
Search Strategy (number of hits): 
1     (ankyl$ adj (spondylo$ or spondyli$)).ti,ab. (447) 
2     (etanercept or enbrel or tnfr-fc).ti,ab,rn. (312) 
3     (infliximab or remicade).ti,ab,rn. (603) 
4     (adalimumab or humira or D2E7).ti,ab,rn. (288) 
5     (golimumab or simponi).ti,ab,rn. (29) 
6     2 or 3 or 4 or 5 (920) 
7     1 and 6 (67) 
8     (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom$).ti,ab. 
(10934) 
9     (expenditure$ not energy).ti,ab. (1038) 
10     (value adj1 money).ti,ab. (2) 
11     budget$.ti,ab. (1712) 
12     8 or 9 or 10 or 11 (13046) 
13     7 and 12 (3) 
Web of knowledge, http://apps.webofknowledge.com, 10th April, 2013 
Number of hits and search strategy: 
# 7  39 
#5 NOT #6 Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09 
# 6  322,154  
TS=(animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovin or sheep or guinea*) 
Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09 
# 5  39 
#4 AND #3 Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09 
# 4  212,671 
TS=(econom* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom* or 
budget*) Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09 
# 3  374 
#2 AND #1 
Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09 
# 2 4,315 
TS=(etanercept or enbrel tnfr-fc or infliximab or remicade or adalimumab or humira or D2E7 or golimumab or 
simponi) 
Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09 
# 1  1,979 
TS=(ankyl* same spondyl*) 
Databases=SCI-EXPANDED, SSCI, A&HCI Timespan=2010-11-01 - 2013-04-09  
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8.8 Results of the health economic literature search (references and 
abstracts) 
 
See file at http://hecon.uni.corvinus.hu 
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